MedMen Enterprises (MMNFQ) 10-Q/A 18 Feb 21 2021 Q1 Quarterly report (amended) Financial data

Cover

Cover - shares	3 Months Ended
	Sep. 26, 2020	Dec. 03, 2020
Cover [Abstract]
Entity Registrant Name	MedMen Enterprises, Inc.
Entity Central Index Key	0001776932
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	The purpose of this Amendment No. 2 on Form 10-Q/A (''Amendment No. 2'') to the MedMen Enterprises Inc. (the ''Company'') Amendment No. 1 to its quarterly report on Form 10-Q/A for the period ended September 26, 2020, filed with the Securities and Exchange Commission (''SEC'' ) on February 17, 2021 (''Amendment No. 1''), is solely to include the correct certification for exhibit 31.2.
Current Fiscal Year End Date	--06-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 26, 2020
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		500,344,220
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Current Assets:
Cash and Cash Equivalents	$ 10,310,260	$ 10,093,925
Restricted Cash	9,873	9,873
Accounts Receivable and Prepaid Expenses	7,192,349	5,626,761
Inventory	21,294,149	22,638,120
Current Assets Held for Sale	30,304,046	33,459,879
Other Current Assets	15,768,919	9,105,457
Due from Related Party	3,109,718	3,109,717
Total Current Assets	87,989,314	84,043,732
Operating Lease Right-of-Use Assets	100,762,121	116,354,828
Property and Equipment, Net	156,197,545	174,547,867
Intangible Assets, Net	138,437,778	148,081,030
Goodwill	33,861,150	33,861,150
Other Assets	16,928,369	17,374,997
TOTAL ASSETS	534,176,277	574,263,604
Current Liabilities:
Accounts Payable and Accrued Liabilities	76,266,738	79,530,930
Income Taxes Payable	57,663,832	38,599,349
Other Current Liabilities	12,572,672	20,278,381
Current Portion of Operating Lease Liabilities	8,206,432	9,757,669
Current Portion of Finance Lease Liabilities	1,418,156	1,644,044
Current Portion of Notes Payable	17,067,303	16,188,668
Current Liabilities Held for Sale	20,345,665	18,659,038
Due to Related Party	4,553,715	4,556,814
Total Current Liabilities	198,094,513	189,214,893
Operating Lease Liabilities, Net of Current Portion	115,297,418	131,045,238
Finance Lease Liabilities, Net of Current Portion	29,701,187	58,569,498
Other Non-Current Liabilities	4,073,875	4,215,533
Deferred Tax Liabilities	46,996,241	48,928,492
Senior Secured Convertible Credit Facility	169,374,611	166,368,463
Notes Payable, Net of Current Portion	162,975,025	152,809,937
TOTAL LIABILITIES	726,512,870	751,152,054
MEZZANINE EQUITY
Super Voting Shares (no par value, unlimited shares authorized, 815,295 and 815,295 shares issued and outstanding as of September 26, 2020 and June 27, 2020, respectively)	82,500	82,500
SHAREHOLDERS' EQUITY:
Preferred Shares (no par value, unlimited shares authorized and no shares issued and outstanding)	0	0
Subordinate Voting Shares (no par value, unlimited shares authorized, 439,396,938 and 403,907,218 shares issued and outstanding as of September 26, 2020 and June 27, 2020, respectively)	0	0
Additional Paid-In Capital	816,321,013	791,172,613
Accumulated Deficit	(649,149,618)	(631,365,866)
Total Equity Attributable to Shareholders of MedMen Enterprises Inc.	167,253,895	159,889,247
Non-Controlling Interest	(359,590,488)	(336,777,697)
TOTAL SHAREHOLDERS' EQUITY	(192,336,593)	(176,888,450)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 534,176,277	$ 574,263,604

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - shares	Sep. 26, 2020	Jun. 27, 2020
Subordinate Voting Shares [Member]
Stockholders' deficit
Preferred stock, shares issued	439,396,938	403,907,218
Preferred stock, shares outstanding	439,396,938	403,907,218
Super Voting Shares [Member]
Stockholders' deficit
Preferred stock, shares issued	815,295	815,295
Preferred stock, shares outstanding	815,295	815,295

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
Unaudited Interim Condensed Consolidated Statements of Operations
Revenue	$ 35,625,968	$ 39,669,996
Cost of Goods Sold	18,801,910	20,277,820
Gross Profit	16,824,058	19,392,176
Expenses:
General and Administrative	31,683,604	54,094,949
Sales and Marketing	193,385	5,782,780
Depreciation and Amortization	8,625,708	9,484,181
Realized and Unrealized Gain on Changes in Fair Value of Contingent Consideration	302,834	2,284,054
Impairment Expense	789,709	0
Gain On Disposals of Assets, Restructuring Fees and Other Expenses	(16,697,861)	(697,962)
Total Expenses	24,897,379	70,948,002
Loss from Operations	(8,073,321)	(51,555,826)
Other Expense (Income):
Interest Expense	11,142,864	8,163,617
Interest Income	(1,210)	(369,342)
Amortization of Debt Discount and Loan Origination Fees	3,202,894	3,067,535
Change in Fair Value of Derivatives	(305,379)	(5,128,420)
Realized and Unrealized Gain on Investments, Assets Held For Sale and Other Assets	(12,415,479)	(11,480,322)
Loss on Extinguishment of Debt	10,129,655	31,570,116
Total Other Expense	11,753,345	25,823,184
Loss from Continuing Operations Before Provision for Income Taxes	(19,826,666)	(77,379,010)
Provision for Income Tax (Expense) Benefit	(10,338,562)	(17,660,731)
Net Loss from Continuing Operations	(30,165,228)	(59,718,279)
Net Loss from Discontinued Operations, Net of Taxes	(2,682,175)	(3,080,420)
Net Loss	(32,847,403)	(62,798,699)
Net Loss Attributable to Non-Controlling Interest	(10,927,541)	(38,575,930)
Net Loss Attributable to Shareholders of MedMen Enterprises Inc.	$ (21,919,862)	$ (24,222,769)
Loss Per Share - Basic and Diluted:
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.	$ (0.06)	$ (0.11)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.	$ (0.01)	$ (0.02)
Weighted-Average Shares Outstanding - Basic and Diluted	423,187,218	191,711,038

Unaudited Interim Condensed C_2

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders Equity - USD ($)	Total	Super Voting [Member]	Subordinate Voting [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	TOTAL EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF MEDMEN [Member]	Noncontrolling Interest
Balance, shares at Jun. 30, 2019		1,630,590	173,010,922
Balance, amount at Jun. 30, 2019	$ 211,270,776	$ 164,999	$ 0	$ 613,356,006	$ (370,382,824)	$ 243,138,181	$ (31,867,405)
Net Loss	(62,798,699)	$ 0	$ 0	0	(24,222,769)	(24,222,769)	(38,575,930)
Controlling Interest Equity Transactions:
At-the-Market Equity Financing Program, Net, shares			4,940,800
At-the-Market Equity Financing Program, Net, amount	8,894,012	$ 0	$ 0	8,894,012	0	8,894,012	0
Shares Issued for Cash, shares			14,634,147
Shares Issued for Cash, amount	30,000,001	$ 0	$ 0	30,000,001	0	30,000,001	0
Shares Issued to Settle Debt, shares			1,231,280
Shares Issued to Settle Debt, amount	2,441,912	$ 0	$ 0	2,441,912	0	2,441,912	0
Equity Component of Debt - New and Amended	2,097,335	$ 0	$ 0	2,097,335	0	2,097,335	0
Redemption of MedMen Corp Redeemable Shares, shares			8,382,618
Redemption of MedMen Corp Redeemable Shares, amount	0	$ 0	$ 0	20,196,142	(19,986,022)	210,120	(210,120)
Shares Issued for Other Assets, shares			225,494
Shares Issued for Other Assets, amount	509,614	$ 0	$ 0	509,614	0	509,614	0
Shares Issued for Acquisition Costs, shares			214,716
Shares Issued for Acquisition Costs, amount	421,497	$ 0	$ 0	421,497	0	421,497	0
Shares Issued for Business Acquisition, shares			5,112,263
Shares Issued for Business Acquisition, amount	9,833,000	$ 0	$ 0	9,833,000	0	9,833,000	0
Stock Grants for Compensation, shares			364,948
Stock Grants for Compensation, amount	875,055	$ 0	$ 0	875,055	0	875,055	0
Share-Based Compensation	3,367,898	0	0	3,367,898	0	3,367,898	0
Non-Controlling Interest Equity Transactions:
Distributions	(310,633)	0	0	0	0	0	(310,633)
Equity Component on Debt and Debt Modification	(1,444,676)						(1,444,676)
Share-Based Compensation	833,531	$ 0	$ 0	0	0	0	833,531
Non-Controlling Interest Equity Transactions:
Equity Component on Debt and Debt Modification	1,444,676						1,444,676
Balance, shares at Sep. 28, 2019		1,630,590	208,117,188
Balance, amount at Sep. 28, 2019	205,990,623	$ 164,999	$ 0	691,992,472	(414,591,615)	277,565,850	(71,575,233)
Balance, amount at Jun. 27, 2020	(176,888,450)
Net Loss	(32,847,403)
Balance, shares at Sep. 26, 2020		815,295	439,396,938
Balance, amount at Sep. 26, 2020	(192,336,593)	$ 82,500	$ 0	816,321,014	(649,149,618)	167,253,895	(359,590,488)
Balance, shares at Jun. 28, 2020		815,295	403,907,218
Balance, amount at Jun. 28, 2020	(176,888,450)	$ 82,500	$ 0	791,172,613	(631,365,865)	159,889,247	(336,777,697)
Net Loss	(32,847,403)	0	0	0	(21,919,862)	(21,919,862)	(10,927,541)
Controlling Interest Equity Transactions:
Equity Component of Debt - New and Amended	21,660,379	$ 0	$ 0	21,660,379	0	21,660,379	0
Redemption of MedMen Corp Redeemable Shares, shares			29,947,959
Redemption of MedMen Corp Redeemable Shares, amount	0	$ 0	$ 0	5,351,262	9,019,576	14,370,838	(14,370,838)
Stock Grants for Compensation, shares			1,318,865
Stock Grants for Compensation, amount	181,589	$ 0	$ 0	181,589	0	181,589	0
Share-Based Compensation	1,008,530	0	0	1,008,530	0	1,008,530	0
Non-Controlling Interest Equity Transactions:
Equity Component on Debt and Debt Modification	(2,485,588)	$ 0	$ 0	0	0	0	(2,485,588)
Controlling Interest Equity Transactions:
Shares Issued to Settle Accounts Payable and Liabilities, shares			3,608,690
Shares Issued to Settle Accounts Payable and Liabilities, amount	516,618	$ 0	$ 0	516,618	0	516,618	0
Shares Issued for Vested Restricted Stock Units, shares			614,207
Shares Issued for Vested Restricted Stock Units, amount	157,477	$ 0	$ 0	157,477	0	157,477	0
Deemed Dividend - Down Round Feature of warrants				4,883,467	(4,883,467)
Deferred Tax Impact On Conversion Feature	(8,610,921)			(8,610,921)		(8,610,921)
Non-Controlling Interest Equity Transactions:
Equity Component on Debt and Debt Modification	2,485,588	$ 0	$ 0	0	0	0	2,485,588
Balance, shares at Sep. 26, 2020		815,295	439,396,938
Balance, amount at Sep. 26, 2020	$ (192,336,593)	$ 82,500	$ 0	$ 816,321,014	$ (649,149,618)	$ 167,253,895	$ (359,590,488)

Unaudited Interim Condensed C_3

Unaudited Interim Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss from Continuing Operations	$ (30,165,228)	$ (59,718,279)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Deferred Tax (Recovery) Expense	(8,749,513)	(78,281)
Depreciation and Amortization	8,688,155	10,394,617
Non-Cash Operating Lease Costs	7,658,920	6,702,802
Accretion of Debt Discount and Loan Origination Fees	3,202,894	3,067,536
Gain on Lease Modifications	(15,919,946)	0
Accretion of Deferred Gain on Sale of Property	(141,659)	(141,656)
Impairment of Assets	789,709	0
Realized and Unrealized Gain on Investments, Assets Held For Sale and Other Assets	(12,415,479)	(11,480,322)
Unrealized Gain on Changes in Fair Value of Contingent Consideration	302,834	2,284,054
Change in Fair Value of Derivative Liabilities	0	(5,128,420)
Loss on Extinguishment of Debt and Settlement of Accounts Payables and Accrued Liabilities	10,129,658	32,230,229
Share-Based Compensation	1,347,604	5,076,470
Shares Issued for Acquisition Costs	0	421,497
Changes in Operating Assets and Liabilities:
Accounts Receivable	(1,565,588)	(1,308,981)
Prepaid Rent - Related Party	0	2,712,237
Prepaid Expenses	(172)	5,630,506
Inventory	1,343,971	(10,849,695)
Other Current Assets	1,994,417	(497,876)
Due from Related Party	0	458,160
Other Assets	446,628	(7,022,876)
Accounts Payable and Accrued Liabilities	(473,753)	10,527,727
Interest Payments on Finance Leases	(1,523,821)	(1,432,930)
Cash Payments - Operating Lease Liabilities	(9,158,398)	(7,172,029)
Income Taxes Payable	19,064,475	(16,207,725)
Other Current Liabilities	8,189,077	(18,654,740)
Due to Related Party	(3,099)	(729,871)
Other Non-Current Liabilities	0	15,870,558
NET CASH USED IN CONTINUED OPERATING ACTIVITIES	(16,958,314)	(45,047,288)
Net Cash (Used in) Provided by Discontinued Operating Activities	(1,194,616)	2,980,952
NET CASH USED IN OPERATING ACTIVITIES	(18,152,930)	(42,066,336)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of Property and Equipment	(201,017)	(17,976,501)
Additions to Intangible Assets	(55,505)	(1,821,936)
Proceeds from Sale of Assets Held for Sale and Other Assets	10,000,000	0
Proceeds from Sale of Property	0	9,300,000
Acquisition of Businesses, Net of Cash Acquired	0	(1,000,000)
Restricted Cash	0	43,477
NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES	9,743,478	(11,454,960)
Net Cash Used in Discontinued Investing Activities	0	(1,694,969)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	9,743,478	(13,149,929)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of Subordinate Voting Shares for Cash	0	38,894,013
Payment of Loan Amendment Fee	0	(500,000)
Proceeds from Issuance of Senior Secured Convertible Credit Facility	4,825,000	25,000,000
Proceeds from Issuance of Notes Payable	4,125,000	11,100,000
Principal Repayments of Notes Payable	(284,334)	(9,940,188)
Principal Repayments of Finance Lease Liability	(39,879)	0
Debt and Equity Issuance Costs	0	(544,498)
(Distributions) Contributions - Non-Controlling Interest	0	(310,633)
NET CASH PROVIDED BY FINANCING ACTIVITIES	8,625,787	63,698,694
NET INCREASE IN CASH AND CASH EQUIVALENTS	216,335	8,482,429
Cash and Cash Equivalents, Beginning of Period	10,093,925	33,753,747
CASH AND CASH EQUIVALENTS, END OF PERIOD	10,310,260	42,236,176
SUPPLEMENTAL DISCLOSURE FOR CASH FLOW INFORMATION
Cash Paid for Interest	3,893,490	10,004,305
Non-Cash Investing and Financing Activities:
Net Assets Transferred to Held for Sale	6,614,987	8,453,664
Receivable Recorded on Asset Held for Sale	9,407,879	0
Adoption of ASC 842 - Leases	0	141,557,231
Lease Termination and Amendments	34,250,918	0
Recognition of Right-of-Use Assets for Finance Leases	350,249	42,676,528
Issuance of Subordinate Voting Shares for Intangible Assets and Other Assets	0	509,614
Redemption of MedMen Corp Redeemable Shares	14,370,838	210,120
Release of Investments for liabilities	750,000	0
Shares Issued to Settle Accounts Payable and Liabilities	516,618	2,028,342
Equity Component of Debt - New and Amended	2,883,786	652,659
Deferred Tax Impact on Conversion Feature	$ 8,610,921	$ 0

NATURE OF OPERATIONS

NATURE OF OPERATIONS	3 Months Ended
	Sep. 26, 2020
NATURE OF OPERATIONS
Note 1. NATURE OF OPERATIONS	MedMen Enterprises Inc. (“MedMen Enterprises” or the “Company”), formerly known as Ladera Ventures Corp., was incorporated under the Business Corporations Act (British Columbia) on May 21, 1987. The Company’s Class B Subordinate Voting Shares are listed on the Canadian Securities Exchange under the symbol “MMEN”, on the OTCQX under the symbol “MMNFF”, on the Frankfurt Stock Exchange under the symbol “OJS.F”, on the Stuttgart Stock Exchange under the symbol “OJS.SG”, on the Munich Stock Exchange under the symbol “OJS.MU”, on the Berlin Stock Exchange under the symbol “OJS.BE” and on the Dusseldorf Stock Exchange under the symbol “OJS.DU”. The head office and principal address of the Company is 10115 Jefferson Boulevard, Culver City, California 90232. The Company’s registered and records office address is 885 West Georgia Street, Suite 2200, Vancouver, British Columbia Canada V6C 3E8. The Company operates through its principal whole-owned subsidiaries, MM CAN USA, Inc., a California corporation (“MM CAN” or “MedMen Corp”), and MM Enterprises USA, LLC, a Delaware limited liability company (“MM Enterprises USA”). MM CAN was converted into a California corporation (from a Delaware corporation) on May 16, 2018 and is based in Culver City, California. The head office and principal address of MM CAN is 10115 Jefferson Boulevard, Culver City, California 90232. MM Enterprises USA was formed on January 9, 2018 and is based in Culver City, California. The head office and principal address of MM Enterprises USA is 10115 Jefferson Boulevard, Culver City, California 90232. MM Enterprises USA was formed as a joint venture whose contributors were MMMG, LLC (“MMMG”); MedMen Opportunity Fund, LP (“Fund I”); MedMen Opportunity Fund II, LP (“Fund II”), The MedMen of Nevada 2, LLC (“MMNV2”); DHSM Investors, LLC (“DHS Owner”); and Bloomfield Partners Utica, LLC (“Utica Owner”) (collectively, the “MedMen Group of Companies”). On January 24, 2018, pursuant to a Formation and Contribution Agreement (the “Agreement”), a roll-up transaction was consummated whereby the assets and liabilities of The MedMen Group of Companies were transferred into MM Enterprises USA. In return, the MedMen Group of Companies received 217,184,382 MM Enterprises USA Class B Units. The Agreement was entered into by and among MM Enterprises Manager, LLC, the sole manager of MM Enterprises USA; MMMG; Fund I; Fund II; MMNV2; DHS Owner; and Utica Owner.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Sep. 26, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Basis of Preparation The accompanying unaudited interim Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). The unaudited interim Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the three months ended September 26, 2020, year ended June 27, 2020 and three months ended September 28, 2019, the consolidated results of operations and cash flows for the three months ended September 26, 2020 and September 28, 2019 have been included. The accompanying unaudited interim Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements, prepared in accordance with GAAP, have been condensed or omitted in accordance with SEC rules and regulations within the instruction to Form 10-Q and Article 10 of Regulation S-X. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in Item 13 of the registration statement on Form 10 for the fiscal year ended June 27, 2020. Going Concern As reflected in the Condensed Consolidated Financial Statements, the Company had an accumulated deficit and a negative net working capital (current liabilities greater than current assets) as of September 26, 2020, as well as a net loss and negative cash flow from operating activities for the reporting period then ended. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these unaudited interim Condensed Consolidated Financial Statements. Management believes that substantial doubt of our ability to meet our obligations for the next twelve months from the date these financial statements were first made available has been alleviated due to, but not limited to, (i) capital raised between December 2020 and December 2021, (ii) restructuring plans that have already been put in place to reduce corporate-level expenses, (iii) debt amendments that have been agreed to with lenders and landlords to defer cash interest and rent payments, (iv) reduction in capital expenditures through a slow-down in new store buildouts, (v) plans to divest non-core assets to raise non-dilutive capital, (vi) enhancements to its digital offering, including direct-to-consumer delivery and curbside pick-up in light of COVID-19 and (vii) a change in retail strategy to pass certain local taxes and payment processing fees to customers. However, management cannot provide any assurances that we will be successful in accomplishing any of our plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase our need to raise additional capital on an immediate basis. The Company will continually monitor its capital requirements based on its capital and operational needs and the economic environment and may raise new capital as necessary. The Company’s ability to continue as a going concern will depend on its ability to raise additional equity or debt in the private or public markets, reducing operating expenses, divesting of certain non-core assets, achieving cash flow profitability. While the Company has been successful in raising equity and debt to date, there can be no assurances that the Company will be successful in completing a financing in the future. If the Company is unable to raise additional capital whenever necessary, it may be forced to divest additional assets to raise capital and/or pay down its debt, amend its debt agreements which could potentially have a dilutive effect on the Company’s shareholders, further reduce operating expenses and temporarily pause the opening of new store locations. Furthermore, COVID-19 and the impact the global pandemic has had and will continue to have on the broader retail environment could also have a significant impact on the Company’s financial operations. COVID-19 On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures worldwide. While the ultimate severity of the outbreak and its impact on the economic environment is uncertain, the Company is monitoring this closely. In the event that the Company were to experience widespread transmission of the virus at one or more of the Company’s store or other facilities, the Company could suffer reputational harm or other potential liability. Further, the Company’s business operations may be materially and adversely affected if a significant number of the Company’s employees are impacted by the virus. Emerging Growth Company The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”) under which emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Functional Currency The Company and its subsidiaries’ functional currency, as determined by management, is the United States (“U.S.”) dollar. These unaudited interim Condensed Consolidated Financial Statements are presented in U.S. dollars as this is the primary economic environment of the group. All references to “C$” refer to Canadian dollars. Significant Accounting Policies The significant accounting policies and critical estimates applied by the Company in these unaudited interim Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in Item 13 of the registration statement on Form 10 for the fiscal year ended June 27, 2020. Restricted Cash Restricted cash balances are those which meet the definition of cash and cash equivalents but are not available for use by the Company. As of September 26, 2020 and June 27, 2020, restricted cash was $9,873 and $9,873, respectively, which is used to pay for lease costs and costs incurred related to building construction in Reno, Nevada. This account is managed by a contractor and the Company is required to maintain a certain minimum balance. Down-Round Provisions The Company calculates down-round features under ASU 2017-11, in which down round features do not meet the criteria for derivative accounting and no liability is to be recorded until an actual issuance of securities triggers the down-round feature. Loss per Share The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, DSU, RSU, warrants and stock options issued. Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments” In January 2017, the FASB issued ASU No. 2017-04 “Intangibles— Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” Recently Issued Accounting Standards In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes”, which eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations. In January 2020, the FASB issued ASU 2020-01, “ Investments – Equity Securities (Topic 321) Investments – Equity Method and Joint Ventures (Topic 323) Derivatives and Hedging (Topic 815) In August 2020, the FASB issued ASU 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible instruments and contracts in an Entity’s Own Equity

INVENTORIES

INVENTORIES	3 Months Ended
	Sep. 26, 2020
INVENTORIES
Note 3. INVENTORIES	As of September 26, 2020 and June 27, 2020, inventory consists of the following: September 26, June 27, 2020 2020 Raw Materials $ 2,671,185 $ 2,055,500 Work-in-Process 9,654,494 8,807,137 Finished Goods 8,968,470 11,775,483 Total Inventory $ 21,294,149 $ 22,638,120

OTHER CURRENT ASSETS

OTHER CURRENT ASSETS	3 Months Ended
	Sep. 26, 2020
OTHER CURRENT ASSETS
Note 4. OTHER CURRENT ASSETS	As of September 26, 2020 and June 27, 2020, other current assets consist of the following: September 26, June 27, 2020 2020 Investments $ 3,036,791 $ 3,786,791 Excise Tax Receivable 3,447,005 5,254,595 Note Receivable 9,171,694 - Other Current Assets 113,429 64,071 Total Other Current Assets $ 15,768,919 $ 9,105,457 As of September 26, 2020 and June 27, 2020, investments included in other current assets consist of the following: ToroVerde Inc. The Hacienda Company, LLC Old Pal Other Investments TOTAL (1) (2) (3) Fair Value as of June 27, 2020 $ - $ 750,000 $ 1,970,000 $ 1,066,791 $ 3,786,791 Settlement of Liabilities - (750,000 ) - - (750,000 ) Fair Value as of September 26, 2020 $ - $ - $ 1,970,000 $ 1,066,791 $ 3,036,791 ________________________ (1) In July 2018, the Company purchased 9,000,000 common shares of ToroVerde Inc., an investment company focused on emerging international cannabis markets, for an aggregate purchase price of $5,000,000, or $0.56 per common share, amounting to 14.3% of the outstanding common shares. As the Company was not deemed to exert any significant influence, the investment was recorded at FVTPL as of September 26, 2020 and June 27, 2020. As of September 26, 2020 and June 27, 2020, the Company holds 14.3% of the equity ownership and voting interests in this investment. (2) In July 2018, the Company purchased units of The Hacienda Company, LLC, a California limited liability company, which owns Lowell Herb Co., a California-based cannabis brand known for its pack of pre-rolls called Lowell Smokes, for an aggregate purchase price of $1,500,000, amounting to 3.2% of the outstanding units. Pursuant to SEC guidance under ASC 323, the application of equity method to investments applies to limited liability companies and are required unless the investor holds less than 3-5%. Accordingly, the Company was deemed to have significant influence resulting in equity method accounting. The Company has elected the fair value option under ASC 825 and the investment was recorded at FVTPL. As of September 26, 2020 and June 27, 2020, the Company holds 3.2% and 0%, respectively, of the equity ownership and voting interests in this investment. (3) In October 2018 and March 2019, the Company purchased an aggregate of 125.3 units of Old Pal, a California-based brand that provides high-quality cannabis flower for its customers, for an aggregate purchase price of $2,000,000, amounting to approximately 10.0% of the outstanding units with 8.7% voting interests. Pursuant to SEC guidance under ASC 323, the application of equity method to investments applies to limited liability companies and are required unless the investor holds less than 3-5%. Accordingly, the Company was deemed to have significant influence resulting in equity method accounting. During the year ended June 27, 2020, the Company decreased their level of ownership in which Old Pal no longer qualified under equity method accounting. The Company has elected the fair value option under ASC 825 and the investment was recorded at FVTPL as of June 27, 2020 and continues to measure Old Pal at the previously elected FVTPL under ASC 323 as of September 26, 2020. As of September 26, 2020, the Company holds 2.6% of the equity ownership and 1.4% of the voting interests in this investment. As of September 26, 2020, the Company’s investment balance in ToroVerde Inc. and The Hacienda Company, LLC was nil and nil, respectively. In August 2020, the Company entered into an agreement to exchange all of its investment in The Hacienda Company, LLC to settle outstanding balances totaling approximately $750,000. The Company determined that the fair value of its investment in Old Pal LLC was $1,970,000 as of September 26, 2020. The fair value of investments included in other current assets is considered a Level 3 categorization in the fair value hierarchy. Investments are measured at fair value using a market approach that is based on unobservable inputs.

ASSETS HELD FOR SALE

ASSETS HELD FOR SALE	3 Months Ended
	Sep. 26, 2020
ASSETS HELD FOR SALE
Note 5. ASSETS HELD FOR SALE	A reconciliation of the beginning and ending balances of assets held for sale for the three months ended September 26, 2020 is as follows: PharmaCann Assets (1) Available for Sale Subsidiaries (2) Discontinued Operations TOTAL Balance at Beginning of Period $ 212,400 $ 12,066,428 $ 21,181,051 $ 33,459,879 Transferred In - 6,614,987 - 6,614,987 Gain on the Sale of Assets Held for Sale - 12,415,479 - 12,415,479 Proceeds from Sale - (19,407,879 ) - (19,407,879 ) Ongoing Activity from Discontinued Operations - (2,300,763 ) (477,657 ) (2,778,420 ) Balance at End of Period $ 212,400 $ 9,388,252 $ 20,703,394 $ 30,304,046 ________________________ (1) During the year ended June 27, 2020, PharmaCann LLC, (“PharmaCann”) transferred 100% of the membership interests for MME Evanston Retail, LLC (“Evanston”), PharmaCann Virginia, LLC (“Staunton”), and PC 16280 East Twombly LLC (“Hillcrest”). As of September 27, 2020, the Company has 100% of membership interests in Staunton which holds land and a license for a vertically-integrated facility in Staunton, Virginia. The Staunton assets were classified as assets held for sale in accordance with ASC 360, “Long-Lived Assets Classified as Held for Sale” and are measured at the lower of its carrying amount or FVLCTS which was determined as $212,400 as of September 26, 2020. (2) Long-lived assets classified as held for sale that do not qualify as discontinued operation and classified as held for sale. Significant classes of assets and liabilities are presented in the notes to the Condensed Consolidated Financial Statements in accordance with ASC 360-10. On July 1, 2020, the Company agreed to transfer all outstanding membership interests in MME Evanston Retail, LLC (“Evanston”) dispensary operation located in Evanston, Illinois to an unaffiliated third party (“Purchaser”). The Company received an aggregate consideration of $20,000,000, of which, $10,000,000 cash was received at closing on July 1, 2020 (“Closing Date”), an additional $8,000,000 cash is due on or before November 16, 2020 and an additional $2,000,000 in the form of a secured promissory note will be payable three months following the Closing Date in exchange for all of the company’s membership interests in Evanston. On August 10, 2020 (“Effective Date”), all operational control and risk of loss was transferred to the Purchaser and the Company had no further obligation to fund operations of Evanston through a Consulting Agreement. Management performed an assessment and determined that the Company no longer has a controlling financial interest as of the Effective Date. The transfer of the cannabis license is pending regulatory approval as of the issuance of these Condensed Consolidated Financial Statements and the Company will take all commercially reasonable steps to maintain all permits for Evanston to operate its business. The Company recognized a gain upon sale of membership interests equal to the difference between the aggregate consideration and the book value of the assets as of the disposition date, less direct costs to sell, which is recognized on the Condensed Consolidated Statements of Operations during the three months ended September 26, 2020. As of September 26, 2020 the Company decided to divest two cannabis licenses and entered into separate agreements to sell 100% of its membership interests in these two locations, located in California, for an aggregate sale price of $5,250,000 of which a non-binding term sheet was entered on June 26, 2020 and $750,000 is to be paid upon the date of close in addition to $750,000 paid in equal monthly installments over twelve months through a promissory note. An additional verbal agreement was entered into during the three months ended September 26, 2020, in which the total consideration to be paid includes $3,500,000 cash paid within thirty days following the date of close and equity consideration equal to $250,000. As of September 26, 2020, the contemplated sale of these locations are pending customary closing conditions and are expected to be completed within a one year period. The assets and liabilities related to these subsidiaries were classified as held for sale in accordance with ASC 360-10 and are measured at the lower of its carrying amount or FVLCTS. In accordance of ASC 360-10, the company performed an analysis of any impairments prior to reclassifying certain assets as held for sale and recorded an impairment charge of $789,709 which is included as a component of impairment expense in the accompanying Condensed Consolidated Statements of Operations. Subsidiaries classified as assets held for sale that do not qualify as discontinued operations as of September 26, 2020 and June 27, 2020 consists of the following: September 26, June 27, 2020 2020 Carrying Amounts of the Assets Included in Assets Held for Sale: Cash and Cash Equivalents $ 7,714 $ 743,271 Prepaid Expenses 4,054 7,798 Inventory - 520,464 Other Current Assets 53,176 81,427 TOTAL CURRENT ASSETS (1) Property and Equipment, Net 326,701 717,952 Operating Lease Right-of-Use Assets 1,042,535 190,986 Intangible Assets, Net 6,115,570 5,227,288 Goodwill 1,838,502 4,577,242 TOTAL NON-CURRENT ASSETS (1) TOTAL ASSETS OF SUBSIDIARIES CLASSIFIED AS HELD FOR SALE $ 9,388,252 $ 12,066,428 Carrying Amounts of the Liabilities Included in Assets Held for Sale: Accounts Payable and Accrued Liabilities $ 137,061 $ 963,255 Income Taxes Payable 85,616 159,053 Other Current Liabilities 2,670 27,854 Current Portion of Operating Lease Liabilities 274,079 - TOTAL CURRENT LIABILITIES (1) Operating Lease Liabilities, Net of Current Portion 1,088,221 296,694 Deferred Tax Liabilities 2,328,367 2,151,879 TOTAL NON-CURRENT LIABILITIES (1) - - TOTAL LIABILITIES OF SUBSIDIARIES CLASSIFIED AS HELD FOR SALE $ 3,916,014 $ 3,598,735 _____________________ (1) The assets and liabilities of subsidiaries classified as held for sale are classified as current on the Condensed Consolidated Balance Sheets as of September 26, 2020 and June 27, 2020 because it is probable that the sale will occur and proceeds will be collected within one year.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Sep. 26, 2020
PROPERTY AND EQUIPMENT
Note 6. PROPERTY AND EQUIPMENT	As of September 26, 2020 and June 27, 2020, property and equipment consists of the following: September 26, June 27, 2020 2020 Land and Buildings $ 37,421,326 $ 37,400,378 Finance Lease Right-of-Use Assets 12,556,847 26,194,566 Furniture and Fixtures 13,991,481 13,970,449 Leasehold Improvements 67,428,253 63,976,372 Equipment and Software 29,496,811 29,277,120 Construction in Progress 35,333,101 38,470,016 Total Property and Equipment 196,227,819 209,288,901 Less Accumulated Depreciation (40,030,274 ) (34,741,034 ) Property and Equipment, Net $ 156,197,545 $ 174,547,867 Depreciation expense related to continuing operations of $5,335,301 and $7,034,650 was recorded for the three months ended September 26, 2020 and September 28, 2019, respectively, of which $62,447 and $942,542, respectively, is included in cost of goods sold. The amount of depreciation recognized for the right of use assets for capital leases during the three months ended September 26, 2020 and September 28, 2019 was $604,280 and $2,070,767, respectively, see “Note 11 – Leases” During the three months ended September 26, 2020 and September 28, 2019, borrowing costs totaling nil and $876,096, respectively, were capitalized using an average capitalization rate of nil and 8.8%, respectively. In addition, during the three months ended September 26, 2020 and September 28, 2019, total labor related costs of $60,620 and $436,164, respectively, were capitalized to Construction in Progress, of which $8,154 and $136,386, respectively, was share-based compensation.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Sep. 26, 2020
INTANGIBLE ASSETS
Note 7. INTANGIBLE ASSETS	As of September 26, 2020 and June 27, 2020, intangible assets consist of the following: September 26, June 27, 2020 2020 Dispensary Licenses $ 133,053,216 $ 139,736,881 Customer Relationships 18,586,200 18,586,200 Management Agreement 7,594,937 7,594,937 Capitalized Software 9,311,278 9,255,026 Intellectual Property 8,520,116 8,520,121 Total Intangible Assets 177,065,747 183,693,165 Dispensary Licenses (21,228,281 ) (19,162,587 ) Customer Relationships (12,480,609 ) (8,113,913 ) Management Agreement (615,347 ) (565,972 ) Capitalized Software (2,862,569 ) (2,273,432 ) Intellectual Property (1,441,163 ) (5,496,231 ) Less Accumulated Amortization (38,627,969 ) (35,612,135 ) Intangible Assets, Net $ 138,437,778 $ 148,081,030 The Company recorded amortization expense related to continuing operations of $3,352,854 and $3,359,970 for the three months ended September 26, 2020 and September 28, 2019, respectively. During the three months ended September 26, 2020 and September 28, 2019, $24,819 and $201,254, respectively, of share-based compensation was capitalized to capitalized software.

OTHER ASSETS

OTHER ASSETS	3 Months Ended
	Sep. 26, 2020
OTHER ASSETS
Note 8. OTHER ASSETS	As of September 26, 2020 and June 27, 2020, other assets consist of the following: September 26, June 27, 2020 2020 Long-Term Security Deposits for Leases $ 9,270,225 $ 9,752,611 Loans and Other Long-Term Deposits 7,563,737 7,568,738 Other Assets 94,407 53,648 Total Other Assets $ 16,928,369 $ 17,374,997

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILTIES	3 Months Ended
	Sep. 26, 2020
ACCOUNTS PAYABLE AND ACCRUED LIABILTIES
Note 9. ACCOUNTS PAYABLE AND ACCRUED LIABILTIES	As of September 26, 2020 and June 27, 2020, accounts payable and accrued liabilities consist of the following: September 26, June 27, 2020 2020 Accounts Payable $ 53,330,661 $ 58,614,619 Accrued Liabilities 9,998,881 10,532,715 Other Accrued Liabilities 12,937,196 10,383,596 Total Other Current Liabilities $ 76,266,738 $ 79,530,930

OTHER CURRENT LIABILITIES AND O

OTHER CURRENT LIABILITIES AND OTHER NON-CURRENT LIABILITIES	3 Months Ended
	Sep. 26, 2020
ACCOUNTS PAYABLE AND ACCRUED LIABILTIES
Note 10. OTHER CURRENT LIABILITIES AND OTHER NON-CURRENT LIABILITIES	As of September 26, 2020 and June 27, 2020, other current liabilities consist of the following: September 26, June 27, 2020 2020 Accrued Interest Payable $ 1,239,976 $ 9,051,650 Contingent Consideration 9,254,634 8,951,801 Derivatives 240,697 546,076 Other Current Liabilities 1,837,365 1,728,854 Total Other Current Liabilities $ 12,572,672 $ 20,278,381 Contingent Consideration Contingent consideration recorded relates to a business acquisition during the year ended June 27, 2020. The contingent consideration related to the acquisition of One Love Beach Club is based upon fair value of the additional shares required to be paid upon the expiration of the lock-up and is based upon the fair market value of the Company’s trading stock and is considered a Level 1 categorization in the fair value hierarchy. Contingent consideration classified as a liability and measured at fair value in accordance with ASC 480, “Distinguishing Liabilities from Equity”. Derivative Liabilities A reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities for the three months ended September 26, 2020 is as follows: September 26, 2020 Balance as of Beginning of Year $ 546,076 Initial Recognition of Derivative Liabilities - Change in Fair Value of Derivative Liabilities (305,379 ) Balance as of End of Year $ 240,697 Fair value was measured based on Level 1 inputs on the fair value hierarchy since there are quoted prices in active markets for these warrants. The Company used the closing price of the publicly-traded warrants to estimate fair value of the derivative liability as of September 26, 2020.

LEASES

LEASES	3 Months Ended
	Sep. 26, 2020
LEASES
Note 11. LEASES	In accordance with ASU 2016-02, the Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right‐of‐use (“ROU”) assets and accrued obligations under operating lease (current and non-current) liabilities in the Condensed Consolidated Balance Sheets. Finance lease ROU assets are included in property and equipment, net and accrued obligations under finance lease (current and noncurrent) liabilities in the Condensed Consolidated Balance Sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets are classified as a finance lease or an operating lease. The Company classifies a lease as an operating lease when it does not meet any of the criteria of a finance lease as set forth by ASU 2016-02. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Most operating leases contain renewal options that provide for rent increases based on prevailing market conditions. The Company has lease extension terms at its properties that have either been extended or are likely to be extended. The terms used to calculate the ROU assets for these properties include the renewal options that the Company is reasonably certain to exercise. The below are the details of the lease cost and other disclosures regarding the Company’s leases as of September 26, 2020 and September 28, 2019: September 26, September 28, 2020 2019 Finance Lease Cost: Amortization of Finance Lease Right-of-Use Assets $ 314,143 $ 2,070,767 Interest on Lease Liabilities 1,523,821 1,432,930 Operating Lease Cost 7,658,920 6,986,299 Total Lease Expenses $ 9,496,884 $ 10,489,996 2020 2019 (Gain) and Loss on Sale and Leaseback Transactions, Net $ - $ (704,207 ) Cash Paid for Amounts Included in the Measurement of Lease Liabilities: Financing Cash Flows from Finance Leases $ 39,879 $ - Operating Cash Flows from Operating Leases $ 9,158,398 $ 7,172,043 Non-Cash Additions to Right-of-Use Assets and Lease Liabilities: Recognition of Right-of-Use Assets for Finance Leases $ 350,249 $ 42,676,528 Recognition of Right-of-Use Assets for Operating Leases $ - $ 141,557,231 2020 2019 Weighted-Average Remaining Lease Term (Years) - Finance Leases 38 48 Weighted-Average Remaining Lease Term (Years) - Operating Leases 8 9 Weighted-Average Discount Rate - Finance Leases 16.22 % 10.66 % Weighted-Average Discount Rate - Operating Leases 13.50 % 11.35 % Future lease payments under non-cancelable operating leases and finance leases as of September 26, 2020 are as follows: Fiscal Year Ending Operating Leases Finance Leases June 26, 2021 $ 23,512,450 $ 3,725,785 June 25, 2022 31,430,045 5,860,696 June 24, 2023 31,536,071 6,035,912 June 29, 2024 41,208,860 11,494,331 June 28, 2025 38,674,115 7,347,736 September 26, 2026 and Thereafter 126,851,773 1,080,067,137 Total Lease Payments 293,213,314 1,114,531,597 Less: Interest (169,709,464 ) (1,083,412,254 ) Present Value of Lease Liability $ 123,503,850 $ 31,119,343 Finance leases noted above contain required security deposits, refer to “Note 8 – Other Assets” Lease Deferral Arrangements On July 2, 2020, the Company modified its existing lease arrangements with the Treehouse Real Estate Investment Trust (the “REIT”) in which the REIT agreed to defer a portion of total current monthly base rent on certain cultivation facilities and ground leases for the 36-month period between July 1, 2020 and July 1, 2023 for a total of four properties. Amendments for two of the properties were accounted for as lease modifications in accordance with ASC modified and ac842 “ Leases Debt Note 12 – Notes Payable

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Sep. 26, 2020
NOTES PAYABLE
Note 12. NOTES PAYABLE	As of September 26, 2020 and June 27, 2020, notes payable consist of the following: September 26, June 27, 2020 2020 Finance liabilities incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum. $ 83,576,661 $ 83,576,661 Non-revolving, senior secured term notes dated between October 1, 2018 and September 16, 2020, issued to accredited investors, which mature on January 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum. 89,464,671 77,675,000 Convertible debentures dated September 16, 2020, issued to accredited investors and qualified institutional buyers, which mature on September 16, 2022, and bear interest at a rate of 7.5% 1,000,000 - Promissory notes dated between January 15, 2019 through March 29, 2019, issued for deferred payments on acquisitions, which mature on varying dates from August 3, 2019 to June 30, 2020 and bear interest at rates ranging from 8.0% to 9.0% per annum. 16,298,250 16,173,250 Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471. 2,057,058 2,339,564 Other 15,419 15,418 Total Notes Payable 192,412,059 179,779,893 Less Unamortized Debt Issuance Costs and Loan Origination Fees (12,369,731 ) (10,781,288 ) Net Amount $ 180,042,328 $ 168,998,605 Less Current Portion of Notes Payable (17,067,303 ) (16,188,668 ) Notes Payable, Net of Current Portion $ 162,975,025 $ 152,809,937 A reconciliation of the beginning and ending balances of notes payable for the three months ended September 26, 2020 and September 28, 2019 is as follows: September 26, 2020 Balance at Beginning of Period $ 168,998,605 Cash Additions 4,125,000 Non-Cash Addition - Debt Modification 877,439 Debt Discount Recognized on Modification (879,267 ) Paid-In-Kind Interest Capitalized 7,912,232 Cash Payments (284,334 ) Equity Component of Debt (2,883,786 ) Cash Paid for Debt Issuance Costs 1,828 Accretion of Debt Discount 2,174,611 Balance at End of Period $ 180,042,328 Less Current Portion of Notes Payable (17,067,303 ) Notes Payable, Net of Current Portion $ 162,975,025 Amendments to Senior Secured Term Loan Facility On July 2, 2020, the Company completed the amendment of its existing term loan facility (the “Facility”) in the principal amount of $77,675,000 with funds managed by Hankey Capital and with an affiliate of Stable Road Capital (the “Lenders”) wherein the entirety of the interest at a rate of 15.5% per annum shall accrue monthly to the outstanding principal as payment-in-kind effective March 1, 2020 through July 2, 2021. Thereafter until maturity on January 31, 2022, one-half of the interest (7.75% per annum) shall be payable monthly in cash and one-half of the interest (7.75% per annum) shall be paid-in-kind. In addition, the Company may request an increase to the Facility through December 31, 2020 to be funded through incremental term loans. Certain reporting and financial covenants were added, and the minimum liquidity covenant was waived until September 30, 2020 wherein the amount of required cash balance thereafter was amended. The amendment to the Facility was not deemed to be a substantial modification under ASC 470-50, “Modifications and Extinguishments” The Company incurred an amendment fee of $834,000 that was added to the outstanding principal balance. As consideration for the amendment, the Company issued approximately 20,227,863 warrants exercisable at $0.34 per share until July 2, 2025. The Company also cancelled 20,227,863 existing warrants held by the lenders exercisable at $0.60 per share until December 31, 2022. The warrants may be exercised at the election of their holders on a cashless basis. The warrants issued in connection with the term loan facility met the scope exception under ASC 815, “Derivatives and Hedging” “Note 15 – Share-Based Compensation” On September 16, 2020, the Company entered into further amendments wherein the amount of funds available under the Facility was increased by $12,000,000, of which $5,700,000 was fully committed by the lenders through October 31, 2020. The additional amounts are funded through incremental term loans at an interest rate of 18.0% per annum wherein 12.0% shall be paid in cash monthly in arrears and 6.0% shall accrue monthly as payment-in-kind. In connection with each incremental draw under the amended Facility, the Company shall issue warrants equal to 200% of the incremental term loan amount, divided by the greater of (a) $0.20 per share and (b) 115% multiplied by the volume-weighted average trading price (“VWAP”) of the shares for the five consecutive trading days ending on the trading day immediately prior to the applicable funding date of the second tranche, which shall be the exercise price of the issued warrant. Such warrants are subject to a down round feature wherein the exercise price would be decreased in the event of the exercise of a down-round price reset of select warrants under the senior secured convertible credit facility with Gotham Green Partners (“GGP”). Refer to “ Note 13 – Senior Secured Convertible Credit Facility “Modifications and Extinguishments” On September 16, 2020, the Company closed on an incremental term loan of $3,000,000 under the amended Facility. As consideration for the amendment, the Company issued approximately 20,227,863 warrants exercisable at $0.34 per share until September 16, 2025. The Company also cancelled 20,227,863 existing warrants held by the lenders exercisable at $0.60 per share until December 31, 2022. In connection with the incremental term loan of $3,000,000, the Company issued 30,000,000 warrants with an exercise price of $0.20 per share until December 31, 2025. The warrants may be exercised at the election of their holders on a cashless basis and are classified as equity instruments. The change in fair value of the warrants was recorded as a debt discount in connection with the Facility. Accordingly, the Company recorded an additional debt discount of $1,579,152 related to the change in terms of the warrants and the incremental term loan. See “Note 15 – Share-Based Compensation” On September 16, 2020, the down round feature on the warrants issued in connection with the incremental term loan of $3,000,000 on September 16, 2020 was triggered wherein the exercise price was adjusted to $0.17 per share. The value of the effect of the down round feature was determined to be $259,736 and recognized as an increase in additional paid-in capital. Unsecured Convertible Facility On September 16, 2020, the Company entered into an unsecured convertible debenture facility for total available proceeds of $10,000,000 wherein the convertible debentures shall have a conversion price equal to the closing price on the trading day immediately prior to the closing date, a maturity date of 24 months from the date of issuance and will bear interest at a rate of 7.5% per annum payable semi-annually in cash. The unsecured facility is callable in additional tranches in the amount of $1,000,000 each, up to a maximum of $10,000,000 under all tranches. The timing of additional tranches can be accelerated based on certain conditions. The Company has the right to prepay, in whole or in part, the outstanding principal amount and accrued interest prior to maturity, upon payment of 7.5% of the principal amount being repaid, less the amount of interest paid during the year of prepayment. The debentures provide for the automatic conversion into Subordinate Voting Shares in the event that the VWAP is greater than $0.25 on the CSE for 45 consecutive trading days, at a conversion price per Subordinate Voting Share equal to $0.17. On September 16, 2020, the Company closed on an initial $1,000,000 of the facility with a conversion price of $0.17 per Subordinate Voting Share. In connection with the initial tranche, the Company issued 3,293,413 warrants with an exercise price of $0.21 per share. Under ASC 815, the conversion option and warrants were recorded as an equity instrument. As of September 26, 2020, the relative fair value of the warrants with a value of $172,153 has been recorded to equity. Financing Liability In connection with the Company’s failed sale and leaseback transactions described in “Note 11 – Leases” Modifications and Extinguishments

SENIOR SECURED CONVERTIBLE CRED

SENIOR SECURED CONVERTIBLE CREDIT FACILITY	3 Months Ended
	Sep. 26, 2020
SENIOR SECURED CONVERTIBLE CREDIT FACILITY
Note 13. SENIOR SECURED CONVERTIBLE CREDIT FACILITY	As of September 26, 2020 and June 27, 2020, senior secured convertible credit facility consists of the following: September 26, June 27, Tranche 2020 2020 Senior secured convertible notes dated April 23, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 1A $ 22,613,719 $ 21,660,583 Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 1B 89,839,938 86,053,316 Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 2 27,740,154 26,570,948 Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 3 10,741,556 10,288,815 Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 4 13,050,118 12,500,000 Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 20,278,293 19,423,593 Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. IA-1 2,835,875 2,734,282 Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. IA-2 5,484,058 - Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 8,560,735 8,199,863 Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 2,040,906 - Total Drawn on Senior Secured Convertible Credit Facility 203,185,352 187,431,400 Less Unamortized Debt Discount (33,810,741 ) (21,062,937 ) Senior Secured Convertible Credit Facility, Net $ 169,374,611 $ 166,368,463 A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the three months ended September 26, 2020 and June 27, 2020 is as follows: Tranche 1 Tranche 2 Tranche 3 Tranche 4 Amendment Fee Notes Restatement Fee Notes 2nd Restatement Fee Notes TOTAL Balance as of June 27, 2020 $ 102,833,447 $ 25,352,687 $ 9,680,433 $ 2,455,231 $ 18,964,600 $ 7,082,065 $ - $ 166,368,463 Cash Additions - - - 4,825,000 - - - 4,825,000 Fees Capitalized to Debt Related to - - - 468,568 - - 2,000,000 2,468,568 Paid-In-Kind Interest Capitalized 4,739,758 1,169,206 452,741 667,205 854,700 360,872 40,906 8,285,388 Net Effect on Equity Component of New (5,440,833 ) (1,492,268 ) (586,606 ) (2,618,335 ) (1,193,896 ) (2,444,153 ) - (13,776,091 ) Cash Paid for Debt Issuance Costs - - - 175,000 - - - 175,000 Amortization of Debt Discounts 261,193 73,947 31,097 585,518 28,685 47,843 - 1,028,283 Balance as of September 26, 2020 $ 102,393,565 $ 25,103,572 $ 9,577,665 $ 6,558,187 $ 18,654,089 $ 5,046,627 $ 2,040,906 $ 169,374,611 On July 2, 2020, the Company amended and restated the securities purchase agreement with Gotham Green Partners (“GGP”) under the senior secured convertible credit facility (the “Convertible Facility”) (the “Fourth Amendment”) wherein the minimum liquidity covenant was waived until September 30, 2020 and resetting at $5,000,000 thereafter with incremental increases on March 31, 2021 and December 31, 2021. The payment-in-kind feature on the Convertible Facility was also extended, such that 100% of the cash interest due prior to June 2021 will be paid-in-kind and 50% of the cash interest due thereafter will be paid-in-kind. The Fourth Amendment released certain assets from its collateral to allow greater flexibility to generate proceeds through the sale of non-core assets. The Fourth Amendment allows for immediate prepayment of amounts under the Convertible Facility with a 5% prepayment penalty until 2nd anniversary of the Fourth Amendment and 3% prepayment penalty thereafter. As part of the Fourth Amendment, holders of notes under the Convertible Facility were provided down-round protection where issuances of equity interests (including securities that are convertible or exchangeable for equity interests) by the Company at less than the higher of (i) lowest conversion price under the amended and restated notes of the Convertible Facility amendment dated March 27, 2020 and (ii) the highest conversion price determined for any incremental advances, will automatically adjust the conversion/exercise price of the previous tranches and incremental tranche 4 warrants and the related replacement warrants to the price of the newly issued equity interests. Certain issuances of equity interests are exempted such as issuances to existing lenders, equity interests in contemplation at the time of Fourth Amendment and equity interests issued to employees, consultants, directors, advisors or other third parties, in exchange for goods and services or compensation. Pursuant to ASU 2017-11, the down-round protection was not considered a derivative and will be recognized when the down-round protection adjustments are triggered. As consideration for the amendment, the conversion price for 52% of the tranches 1 through 3 and the first amendment fee notes outstanding under the Convertible Facility were amended to $0.34 per share. An amendment fee of $2,000,000 was also paid through the issuance of additional notes at a conversion price of $0.28 per share. The Fourth Amendment to the Convertible Facility was deemed to be a substantial modification under ASC 470-50, “Modifications and Extinguishments,” On September 14, 2020, the Company closed on an incremental advance in the amount of $5,000,000 under its existing Convertible Facility with GGP at a conversion price of $0.20 per share. In connection with the incremental advance, the Company issued 25,000,000 warrants with an exercise price of $0.20 per share. In addition, 1,080,255 Existing warrants were cancelled and replaced with 16,875,001 warrants with an exercise price of $0.20 per share. Pursuant to the terms of the GGP Facility, the conversion price for 5.0% of the existing Notes outstanding prior to Tranche 4 and Incremental Advance (including paid-in-kind interest accrued on such Notes), being 5.0% of an aggregate principal amount of $170,729,923, was amended to $0.20 per share. As consideration for the additional advance, the Company issued convertible notes as consideration for a $468,564 fee with a conversion price of $0.20 per share. On September 16, 2020, the down round feature on the convertible notes and warrants issued in connection with Tranche 4, Incremental Advances and certain amendment fees was triggered wherein the exercise price was adjusted to $0.17 per share. The value of the effect of the down round feature on convertible notes and warrants was determined to be $21,672,272 and $4,883,467, respectively. The effect related to convertible notes was recognized as additional debt discount and an increase in additional paid-in-capital. The effect related to warrants was recognized as a deemed distribution and an increase in additional paid-in capital.

SHAREHOLDERS EQUITY

SHAREHOLDERS EQUITY	3 Months Ended
	Sep. 26, 2020
MEZZANINE EQUITY
Note 14. SHAREHOLDERS' EQUITY	Issued and Outstanding A reconciliation of the beginning and ending issued and outstanding shares is as follows: Subordinate Voting Shares Super Voting Shares MM CAN USA Class B Redeemable Units MM Enterprises USA Common Units Balance as of June 27, 2020 403,907,218 815,295 236,123,851 725,016 Shares Issued to Settle Accounts Payable and Liabilities 3,608,690 - - - Redemption of MedMen Corp Redeemable Shares 29,947,959 - (29,947,959 ) - Shares Issued for Vested Restricted Stock Units 614,207 - - - Stock Grants for Compensation 1,318,865 - - - Balance as of September 26, 2020 439,396,939 815,295 206,175,892 725,016 Non-Controlling Interests Non-controlling interest represents the net assets of the subsidiaries that the holders of the Subordinate Voting Shares do not directly own. The net assets of the non-controlling interest are represented by the holders of MM CAN USA Redeemable Shares and the holders of MM Enterprises USA Common Units. Non-controlling interest also represents the net assets of the entities the Company does not directly own but controls through a management agreement. As of September 26, 2020 and June 27, 2020, the holders of the MM CAN USA Redeemable Shares represent approximately 31.94% and 36.89%, respectively, of the Company and holders of the MM Enterprises USA Common Units represent approximately 0.11% and 0.11%, respectively, of the Company. Variable Interest Entities The below information are entities the Company has concluded to be variable interest entities (“VIEs”) as the Company possesses the power to direct activities through management services agreements (“MSAs”). Through these MSAs, the Company can significantly impact the VIEs and thus holds a controlling financial interest. The following table represents the summarized financial information about the Company’s consolidated VIEs. VIEs include the balances of LAX Fund II Group, LLC, Natures Cure, Inc. and Venice Caregiver Foundation, Inc. This information represents amounts before intercompany eliminations. As of and for the three months ended September 26, 2020, the balances of the VIEs consists of the following: Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 912,450 $ (4,268,671 ) $ 5,913,332 $ 2,557,111 Non-Current Assets 13,890,323 3,188,194 5,011,523 22,090,040 Total Assets 14,802,773 (1,080,477 ) 10,924,855 24,647,151 Current Liabilities $ 12,471,726 $ 3,142,212 $ 1,895,769 $ 17,509,707 Non-Current Liabilities 9,142,143 2,611,035 1,146,331 12,899,509 Total Liabilities 21,613,869 5,753,247 3,042,100 30,409,216 Non-Controlling Interest $ (6,811,096 ) $ (6,833,724 ) $ 7,882,755 $ (5,762,065 ) Revenues $ 2,245,915 $ (570 ) $ 3,438,820 $ 5,684,165 Net (Loss) Income Attributable to Non-Controlling Interest $ (885,911 ) $ (763,397 ) $ 1,103,128 $ (546,180 ) As of and for the year ended June 27, 2020, the balances of the VIEs consists of the following: Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 1,233,188 $ 811,025 $ 6,639,231 $ 8,683,444 Non-Current Assets 16,867,824 3,259,563 5,032,428 25,159,815 Total Assets 18,101,012 4,070,588 11,671,659 33,843,259 Current Liabilities $ 12,831,161 $ 7,481,953 $ 3,745,710 $ 24,058,824 Non-Current Liabilities 11,196,585 2,662,078 1,146,322 15,004,985 Total Liabilities 24,027,746 10,144,031 4,892,032 39,063,809 Non-Controlling Interest $ (5,926,734 ) $ (6,073,443 ) $ 6,779,627 $ (5,220,550 ) Revenues $ 10,949,458 $ - $ 13,976,810 $ 24,926,268 Net (Loss) Income Attributable to Non-Controlling Interest $ (6,132,528 ) $ (3,777,079 ) $ 3,143,437 $ (6,766,170 ) The net change in the consolidated VIEs and other non-controlling interest are as follows for the three months ended September 26, 2020: Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. Other Non- Controlling Interests TOTAL Balance as of June 27, 2020 $ (5,925,185 ) $ (6,070,327 ) $ 6,779,627 $ (331,561,812 ) $ (336,777,697 ) Net Income (Loss) (885,911 ) (763,397 ) 1,103,128 (10,381,361 ) (10,927,541 ) Equity Component on Debt and Debt Modification - - - 2,485,588 2,485,588 Redemption of MedMen Corp Redeemable Shares - - - (14,370,838 ) (14,370,838 ) Balance as of September 26, 2020 $ (6,811,096 ) $ (6,833,724 ) $ 7,882,755 $ (353,828,423 ) $ (359,590,488 ) Le Cirque Rouge, LP (the Operating Partnership,” or the “OP”) is a Delaware limited partnership that holds substantially all of the real estate assets owned by the REIT, conducts the REIT’s operations, and is financed by the REIT. Under ASC 810, “Consolidation” “Note 11 – Leases”

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	3 Months Ended
	Sep. 26, 2020
SHARE-BASED COMPENSATION
Note 15. SHARE-BASED COMPENSATION	The Company has a stock and equity incentive plan (the “Incentive Plan”) under which the Company may issue various types of equity instruments to any employee, officer, consultant, advisor or director. The types of equity instruments issuable under the Incentive Plan encompass, among other things, stock options, stock grants, deferred stock units, restricted stock grants, LTIP, P units and warrants (together, “Awards”). Stock based compensation expenses are recorded as a component of general and administrative To the extent that the Company has not appointed a Compensation Committee, all rights and obligations under the Incentive Plan shall be those of the full Board of Directors. The maximum number of Awards that may be issued under the Incentive Plan shall be determined by the Compensation Committee or the Board of Directors in the absence of a Compensation Committee. Any shares subject to an Award under the Incentive Plan that are forfeited, canceled, expire unexercised, are settled in cash, or are used or withheld to satisfy tax withholding obligations, shall again be available for Awards under the Incentive Plan. Vesting of Awards will be determined by the Compensation Committee or Board of Directors in absence of one. The exercise price for Awards (if applicable) will generally not be less than the fair market value of the Award at the time of grant and will generally expire after 10 years. A summary of share-based compensation expense for the three months ended September 26, 2020 and September 28, 2019 is as follows: Three Months Ended September 26, September 28, 2020 2019 Stock Options $ 1,008,538 $ 1,687,273 LTIP Units - 833,531 Stock Grants for Services 181,589 364,948 Restricted Stock Grants 157,477 1,680,625 Total Share-Based Compensation $ 1,347,604 $ 4,566,377 Stock Options A reconciliation of the beginning and ending balance of stock options outstanding is as follows: Number of Stock Options Weighted-Average Exercise Price Number of Stock Options Exercisable Weighted-Average Exercise Price Balance as of June 27, 2020 8,618,204 $ 2.78 4,248,393 $ 2.78 Granted - $ - 896,857 $ 3.48 Forfeited (717,794 ) $ (3.26 ) - $ - Balance as of September 26, 2020 7,900,410 $ 2.74 5,145,250 $ 3.24 The aggregate intrinsic value of options outstanding was nil at both September 26, 2020 and June 27, 2020. LTIP Units and LLC Redeemable Units A reconciliation of the beginning and ending balances of the LTIP Units and LLC Redeemable Units issued for compensation outstanding is as follows: Weighted LTIP Units LLC Average Issued and Redeemable Grant Date Outstanding Units Fair Value Balance as of June 27, 2020 and September 26, 2020 19,323,878 725,016 $ 0.52 Deferred Stock Units Effective December 10, 2019, the Company’s board of directors approved a Deferred Share Unit (“DSU”) award under the Company’s Incentive Plan. The DSU award was for units to the Company’s non-management directors. Each director will be provided the Company’s Subordinate Voting Shares based on the duration of their term as a director up to $250,000 for a year of service ending August 2020. At September 26, 2020 and June 27, 2020, there was 1,283,567 units issued and outstanding. For the three months ended September 26, 2020 and September 28, 2019, compensation expense related to the DSU award was nil, was included in accounts payable and stock based compensation expense on the Company’s Condensed Consolidated Balance Sheets. As of September 26, 2020, the corresponding Subordinate Voting Share have not yet been issued to the directors. A reconciliation of the beginning and ending balance of DSUs outstanding is as follows: Issued and Outstanding Weighted- Average Fair Value Balance as of June 27, 2020 1,283,567 $ 0.38 Granted - $ - Balance as of September 26, 2020 1,283,567 $ 0.38 Restricted Stock Grants During the three months ended September 26, 2020 and September 28, 2019, the Company granted an entitlement to 614,207 and 178,190, respectively, of restricted Subordinate Voting Shares to certain officers and directors. A reconciliation of the beginning and ending balance of restricted stock grants outstanding is as follows: Issued and Outstanding Vested Weighted- Average Fair Value Balance as of June 27, 2020 7,159,164 192,459 $ 0.68 Granted 614,207 - $ 0.29 Redemption of Vested Stock (614,207 ) (614,207 ) $ 0.29 Vesting of Restricted Stock - 628,873 $ 0.35 Balance as of September 26, 2020 7,159,164 207,125 $ 0.68 Certain restricted stock granted has vesting which is based on market conditions. For restricted stock that have no market condition vesting, the fair value was determined using the trading value of the Subordinate Voting Shares on the date of grant. For the restricted stock that have market condition vesting, these shares were valued using a Monte Carlo simulation model taking into account the trading value of the Company’s Subordinate Voting Shares on the date of grant and into the future encompassing a wide range of possible future market conditions. Warrants A reconciliation of the beginning and ending balance of warrants outstanding is as follows: Number of Warrants Outstanding Subordinate Voting Shares MedMen Corp Redeemable Shares Total Weighted-Average Exercise Price Balance as of June 27, 2020 114,998,915 40,455,731 155,454,646 $ 0.59 Issued 110,757,575 70,455,726 181,213,301 $ 0.17 Cancelled (1,080,226 ) (40,455,731 ) (41,535,957 ) $ (0.50 ) Balance as of September 26, 2020 224,676,264 70,455,726 295,131,990 $ 0.34 During the three months ended September 26, 2020, 40,455,726 and 30,000,000 warrants were issued for MedMen Corp Redeemable Shares with an exercise price of $0.34 and $0.20, respectively, and expire through September 16, 2025. Additionally, 41,875,000, 3,293,413 and 3,500,000 warrants were issued for Subordinate Voting Shares with an exercise price of $0.20, $0.21 and $0.34, respectively, and expire through July 2, 2025. The fair value of warrants exercisable for MedMen Corp Redeemable Shares was determined using the Black-Scholes option-pricing model with the following assumptions on the date of issuance: September 26, June 27 2020 2020 Weighted-Average Risk-Free Annual Interest Rate 0.12 % 2.82 % Weighted-Average Expected Annual Dividend Yield 0 % 0 % Weighted-Average Expected Stock Price Volatility 91.38 % 82.93 % Weighted-Average Expected Life of Warrants 1 year 1 year The fair value of warrants exercisable for the Company’s Subordinate Voting Shares was determined using the Black-Scholes option-pricing model with the following assumptions on the latest modification of September 16, 2020: Weighted-Average Risk-Free Annual Interest Rate 0.08 % Weighted-Average Expected Annual Dividend Yield 0 % Weighted-Average Expected Stock Price Volatility 52.84 % Weighted-Average Expected Life of Warrants 0.6 year Stock price volatility was estimated by using the historical volatility of the Company’s Subordinate Voting Shares and the average historical volatility of comparable companies from a representative peer group of publicly-traded cannabis companies. The expected life in years represents the period of time that warrants issued are expected to be outstanding. The risk-free rate was based on U.S. Treasury bills with a remaining term equal to the expected life of the warrants. 80,838,323 of warrants are cancelable if the Company meets certain cash flow metrics for two consecutive quarters. The effects of contingent cancellation feature were included in determining the fair value of the related warrants. As of September 26, 2020 and June 27, 2020, warrants outstanding have a weighted-average remaining contractual life of 53.8 and 46.2 months, respectively.

LOSS PER SHARE

LOSS PER SHARE	3 Months Ended
	Sep. 26, 2020
LOSS PER SHARE
Note 16. LOSS PER SHARE	The following is a reconciliation for the calculation of basic and diluted loss per share for the three months ended September 26, 2020 and September 28, 2019: Three Months Ended September 26, September 28, 2020 2019 Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. $ (19,237,687 ) $ (21,142,349 ) Less: Deemed Dividend - Down Round Feature of Warrants (4,883,467 ) - Net Loss from Continuing Operations Available to Shareholders of MedMen Enterprises, Inc. $ (24,121,154 ) $ (21,142,349 ) Net Loss from Discontinued Operations (2,682,175 ) (3,080,420 ) Weighted-Average Number of Shares Outstanding 423,187,218 191,711,038 Earnings (Loss) Per Share - Basic and Diluted: From Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. $ (0.06 ) $ (0.11 ) From Discontinued Operations $ (0.01 ) $ (0.02 ) Diluted loss per share is the same as basic loss per share as the issuance of shares on the exercise of convertible debentures, LTIP share units, warrants and share options is anti-dilutive.

GENERAL AND ADMINISTRATIVE EXPE

GENERAL AND ADMINISTRATIVE EXPENSES	3 Months Ended
	Sep. 26, 2020
GENERAL AND ADMINISTRATIVE EXPENSES
Note 17. GENERAL AND ADMINISTRATIVE EXPENSES	During the three months ended September 26, 2020 and September 28, 2019, general and administrative expenses consisted of the following: September 26, 2020 September 28, 2019 Salaries and Benefits $ 10,040,704 $ 20,901,335 Professional Fees 3,599,335 5,285,269 Rent 8,607,733 7,134,515 Licenses, Fees and Taxes 3,250,878 2,321,899 Other General and Administrative 6,184,954 18,451,931 Total General and Administrative Expenses $ 31,683,604 $ 54,094,949

PROVISION FOR INCOME TAXES AND

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES	3 Months Ended
	Sep. 26, 2020
PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES
Note 18. PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES	The following table summarizes the Company’s income tax expense and effective tax rates for the three months ended September 26, 2020 and September 28, 2019: Three Months Ended September 26, 2020 September 28, 2019 Loss from Continuing Operations Before Provision for Income Taxes $ (19,826,666 ) $ (77,379,010 ) Income Tax (Expense) Benefit (10,338,562 ) 17,660,731 Effective Tax Rate (52.04 )% (22.82) % Historically, the Company has computed its provision for income taxes under the discrete method which treats the year-to-date period as if it were the annual period and determines the income tax expense or benefit on that basis. For the three months ended September 26, 2020, the Company has calculated its provision for income taxes during its interim reporting periods by applying an estimate of the annual effective tax rate for the full year “ordinary” income or loss for the respective reporting period. Historically, the discrete method was applied due to the reliability of the estimate the annual effective tax rate. The Company believes that, at this time, the use of the estimated annual tax rate is more appropriate under FASB Interpretation No. 18 an interpretation of APB Opinion No. 28 than the discrete method given the Company’s utilization of its forecast. As the Company operates in the legal cannabis industry, the Company is subject to the limits of IRC Section 280E for U.S. federal, Illinois state, Florida state and New York state income tax purposes under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. However, the State of California does not conform to IRC Section 280E and, accordingly, the Company deducts all operating expenses on its California Franchise Tax Returns. Since IRC Section 280E was not applied in the California Franchise Tax returns, the Company has approximately $76,700,000 of gross California net operating losses which begin expiring in 2038 as of June 27, 2020. The Company has evaluated the realization of its California net operating loss tax attribute and has determined under the more likely than not standard that $2,500,000 will not be realized. The effective tax rate for the three months ended September 26, 2020 varies widely from the three months ended September 28, 2019, respectively, primarily due to the Company reporting increased expenses subject to IRC Section 280E relative to pre-tax book loss. The Company incurred a large amount of expenses that were not deductible due to IRC Section 280E limitations which resulted in income tax expense being incurred while there were pre-tax losses for the three months ended September 26, 2020. The federal statute of limitation remains open for the 2017 tax year to the present. The state income tax returns generally remain open for the 2016 tax year through the present. Net operating losses arising prior to these years are also open to examination if and when utilized.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Sep. 26, 2020
COMMITMENTS AND CONTINGENCIES
Note 19. COMMITMENTS AND CONTINGENCIES	Contingencies The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of these regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local and state regulations as of September 26, 2020 and June 27, 2020, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future. Claims and Litigation From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of September 26, 2020, there were no pending or threatening lawsuits that could be reasonably assessed to have resulted in a probable loss to the Company in an amount that can be reasonably estimated. As such, no accrual has been made in the Consolidated Financial Statements relating to claims and litigations. As of September 26, 2020, there are also no proceedings in which any of the Company’s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company’s interest. In July 2018, a legal claim was filed against the Company related to alleged misrepresentations in respect of a financing transaction completed in May 2018. The claimant is seeking damages of approximately $2,200,000. The Company believes the likelihood of a loss contingency is remote. As a result, no amount has been set up for potential damages in these financial statements. In late January 2019, the Company’s former Chief Financial Officer (“CFO”) filed a complaint against MM Enterprises in the Superior Court of California, County of Los Angeles, seeking damages for claims relating to his employment. The Company is currently defending against this lawsuit, which seeks damages for wrongful termination, breach of contract, and breach of implied covenant of good faith. The former CFO’s employment agreement provided for the payment of severance in the event of termination without cause. The Company disputes the claims set forth in this lawsuit and believes that the outcome is neither probable nor estimable; therefore, no amounts have been accrued in relation to the claim. In March 2020, litigation was filed against the Company related to a purchase agreement for a previous acquisition. The Company is currently defending against this lawsuit, which seeks damages for fraudulent inducement and breach of contract. The Company believes the likelihood of a loss contingency is neither probable nor remote and the amount cannot be estimated reliably. As such, no amount has been accrued in these financial statements. In May 2020, litigation was filed against the Company related to a purchase agreement and secured promissory note for a previous acquisition. The Company is currently defending against this lawsuit, which claims for breach of contract, breach of implied covenant of good faith and fair dealing, common law fraud and securities fraud. The plaintiffs are seeking damages for such claims in which the amount is currently not reasonably estimable. Therefore, pursuant to ASC 450, “ Contingencies Note 22 – Discontinued Operations In September 2020, a legal dispute was filed against the Company related to the separation of a former officer in which the severance issued is currently being disputed. The Company believes the likelihood of loss is remote. As a result, no amount has been set up for potential damages in these financial statements. A legal dispute has been filed against the Company and is currently in arbitration. The dispute is at an early stage and the Company believes that a loss contingency as a result of the settlement is reasonably possible; however the amount is not estimable. Accordingly, no amount has been accrued in relation to the dispute.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Sep. 26, 2020
RELATED PARTY TRANSACTIONS
Note 20. RELATED PARTY TRANSACTIONS	All related party balances due from or due to the Company as of September 26, 2020 and June 27, 2020 did not have any formal contractual agreements regarding payment terms or interest. As of September 26, 2020 and June 27, 2020, amounts due from related parties were as follows: September 26, June 27, Name and Relationship to Company Transaction 2020 2020 MMOF GP II, LLC (“Fund LP II”), an entity which Mr. Adam Bierman, Mr. Andrew Modlin and Mr. Christopher Ganan each holds 33.3% indirect voting interest. The shareholders each hold 27.1% of indirect equity interest in Fund LP II, the General Partner of Fund II, which both hold equity interests in a subsidiary of the Company. (1) Management Fees $ 1,820,204 $ 1,820,204 MedMen Opportunity Fund GP, LLC (“Fund LP”), an entity which Mr. Adam Bierman, Mr. Andrew Modlin and Mr. Christopher Ganan each holds 33.3% indirect voting interest. The shareholders each hold 24.2% of indirect equity interest in Fund LP, the General Partner of Fund I, which both hold equity interests in a subsidiary of the Company. (1) Management Fees 1,289,514 1,289,513 Total Amounts Due from Related Parties $ 3,109,718 $ 3,109,717 _____________________ (1) As of February 2020 and May 2020, Mr. Adam Bierman and Mr. Andrew Modlin, respectively, no longer held board or management positions and therefore as of September 26, 2020 are not related parties, however they were during the fiscal year ended June 27, 2020. As of September 26, 2020, Chris Ganan is a member of the Company’s board of directors and thus considered a related party under ASC 850, “Related Party Disclosures”. As of September 26, 2020 and June 27, 2020, amounts due to related parties were as follows: September 26, June 27, Name and Relationship to Company Transaction 2020 2020 Fund LP II, an entity which Mr. Adam Bierman, Mr. Andrew Modlin and Mr. Christopher Ganan each holds 33.3% indirect voting interest. The shareholders each hold 27.1% of indirect equity interest in Fund LP II, the General Partner of Fund II, which both hold equity interests in a subsidiary of the Company. (1) Working Capital, Construction and Tenant Improvements, Lease Deposits and Cash Used for Acquisitions $ (1,093,896 ) $ (1,093,896 ) Fund LP, an entity which Mr. Adam Bierman, Mr. Andrew Modlin and Mr. Christopher Ganan each holds 33.3% indirect voting interest. The shareholders each hold 24.2% of indirect equity interest in Fund LP, the General Partner of Fund I, which both hold equity interests in a subsidiary of the Company. (1) Working Capital, Management Fees and Cash Used for Acquisitions (1,986,697 ) (1,986,697 ) Other (1,473,122 ) (1,476,221 ) Total Amounts Due to Related Parties $ (4,553,715 ) $ (4,556,814 ) _____________________ (1) As of February 2020 and May 2020, Mr. Adam Bierman and Mr. Andrew Modlin, respectively, no longer held board or management positions and therefore as of September 26, 2020 are not related parties, however they were during the fiscal year ended June 27, 2020. As of September 26, 2020, Chris Ganan is a member of the Company’s board of directors and thus considered a related party under ASC 850, “Related Party Disclosures”. On December 11, 2019, the Company announced that Benjamin Rose, the Executive Chairman of the Board, was granted a limited proxy of 815,295 Class A Super Voting Shares, which represents 50% of the total Class A Super Voting Shares, for a period of one year. As a result of the proxy, Mr. Rose has joint control of the Company. Under ASC 850, “Related Party Disclosures” As of September 26, 2020, the Company determined GGP to be a related party as a result of GGP having significant influence over the Company. See “Note 13 – Senior Secured Convertible Credit Facility” In March 2020, the Company entered into restructuring plan and retained interim management and advisory firm, Sierra Constellation Partners (“SCP”). As part of the engagement, Tom Lynch was appointed as Interim Chief Executive Officer and Chief Restructuring Officer, and Tim Bossidy was appointed as Interim Chief Operating Officer. Mr. Lynch is a Partner and Senior Managing Director at SCP. Mr. Bossidy is a Director at SCP. As of September 26, 2020, the Company had paid $699,322 in fees to SCP for interim management and restructuring support.

SEGMENTED INFORMATION

SEGMENTED INFORMATION	3 Months Ended
	Sep. 26, 2020
Note 21. SEGMENTED INFORMATION	The Company currently operates in one segment, the production and sale of cannabis products, which is how the Company’s Chief Operating Decision Maker managers the business and makes operating decisions. The Company’s cultivation operations are not considered significant to the overall operations of the Company. Intercompany sales and transactions are eliminated in consolidation.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	3 Months Ended
	Sep. 26, 2020
DISCONTINUED OPERATIONS
Note 22. DISCONTINUED OPERATIONS	During the fiscal second quarter of 2020, the Company contemplated the divesture of non-core assets and management entered into a plan to sell its operations in the state of Arizona. During the fiscal year ended June 27, 2020, the Company entered into binding and non-binding term sheets and began separate negotiations to sell its operations in the state of Arizona, including the related management entities, for total gross proceeds of approximately $25,500,000. As of September 26, 2020, the contemplated transactions are subject to customary closing conditions and is expected to close within the next twelve months. After the close of the transaction, there will be no continued involvement with the sellers. Consequently, assets and liabilities allocable to the operations within the state of Arizona were classified as a disposal group. The assets associated with the Arizona disposal group have been measured at the lower of its carrying amount or FVLCTS. Revenue and expenses, gains or losses relating to the discontinuation of Arizona operations have been eliminated from profit or loss from the Company’s continuing operations and are shown as a single line item in the Consolidated Statements of Operations. For the fiscal first quarter of 2021, net loss from discontinued operations does not include revenue and expenses and gains or losses from Kannaboost Technology Inc. and CSI Solutions LLC (collectively referred to as “Level Up”), which include retail locations in Scottsdale and Tempe and cultivation and production facilities in Tempe and Phoenix. Refer to “ Note 19 - Commitments and Contingencies The Company will continue to operate the Arizona operations until the ultimate sale of the disposal group. Net operating loss of the discontinued operations and the gain or loss from re-measurement of assets and liabilities classified as held for sale are summarized as follows: September 26, September 28, 2020 2019 Revenue $ 1,599,990 $ 4,304,749 Cost of Goods Sold 1,268,752 3,880,606 Gross Profit 331,238 424,143 Expenses: General and Administrative 976,611 1,823,752 Sales and Marketing 6,501 948 Depreciation and Amortization 49,142 499,328 Total Expenses 1,032,254 2,324,028 Income (Loss) from Operations (701,016 ) (1,899,885 ) Other Expense (Income): Other Expense 37,056 5,385 Total Other Expense 37,056 5,385 Loss on Discontinued Operations Before Provision for Income Taxes (738,072 ) (1,905,270 ) Provision for Income Tax (Expense) Benefit (1,944,103 ) (1,175,150 ) Loss on Discontinued Operations $ (2,682,175 ) $ (3,080,420 ) The carrying amounts of assets and liabilities in the disposal group are summarized as follows: September 26, June 27, 2020 2020 Carrying Amounts of the Assets Included in Discontinued Operations: Cash and Cash Equivalents $ 319,834 $ 522,966 Accounts Receivable 239,702 274,886 Prepaid Expenses 59,921 74,622 Inventory 3,241,697 3,323,978 Other Current Assets 65,851 64,600 TOTAL CURRENT ASSETS (1) Property and Equipment, Net 4,224,082 4,288,808 Operating Lease Right-of-Use Assets 5,136,228 5,257,327 Intangible Assets, Net 7,298,804 7,260,288 Other Assets 117,275 113,576 TOTAL NON-CURRENT ASSETS (1) TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 20,703,394 $ 21,181,051 Carrying Amounts of the Liabilities Included in Discontinued Operations: Accounts Payable and Accrued Liabilities $ 1,732,280 $ 2,126,162 Income Taxes Payable 2,818,170 946,679 Other Current Liabilities 22,462 22,747 Current Portion of Operating Lease Liabilities 379,529 385,699 TOTAL CURRENT LIABILITIES (1) Operating Lease Liabilities, Net of Current Portion 5,199,132 5,300,936 Deferred Tax Liabilities 6,278,078 6,278,079 TOTAL NON-CURRENT LIABILITIES (1) TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 16,429,651 $ 15,060,302 _____________________ (1) The assets and liabilities of the disposal group classified as held for sale are classified as current on the Condensed Consolidated Balance Sheets as of September 26, 2020 because it is probable that the sale will occur and proceeds will be collected within one year.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Sep. 26, 2020
SUBSEQUENT EVENTS
Note 23. SUBSEQUENT EVENTS	The Company has evaluated subsequent events through December 7, 2020, which is the date these unaudited interim Condensed Consolidated Financial Statements were issued, and has concluded that the following subsequent events have occurred that would require recognition in the Consolidated Financial Statements or disclosure in the notes to the Consolidated Financial Statements. Senior Secured Term Loan Facility On October 30, 2020, the Company closed on incremental term loans totaling approximately $7,700,000 under its existing Facility with Hankey Capital at an interest rate of 18.0% per annum of which 12.0% shall be paid in cash monthly in arrears; and 6.0% shall accrue monthly to the outstanding principal as payment-in-kind. In connection with the funding, the Company issued 77,052,790 warrants each exercisable at $0.20 per share for a period of five years. Unsecured Convertible Facility On September 28, 2020, the Company closed on a second tranche of $1,000,000 under its existing unsecured convertible facility with a conversion price of $0.17 per Subordinate Voting Share. In connection with the second tranche, the Company issued 3,777,475 warrants with an exercise price of $0.21 per Subordinate Voting Share. On November 20, 2020, the Company closed on a third tranche of $1,000,000 under the facility with a conversion price of $0.17 per Subordinate Voting Share. In connection with the third tranche, the Company issued 3,592,326 warrants with an exercise price of $0.21 per share. Sale of Assets Subsequent to September 26, 2020, Level Up was sold at auction for a sales price of approximately $25,000,000.

RECLASSIFICATIONS

RECLASSIFICATIONS	3 Months Ended
	Sep. 26, 2020
Note 24. RECLASSIFICATIONS	Certain comparative amounts have been reclassified to conform with current period presentation.

CORRECTION OF ERROR IN PREVIOUS

CORRECTION OF ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS	3 Months Ended
	Sep. 26, 2020
Note 25. CORRECTION OF ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS	Subsequent to the issuance of the unaudited interim Condensed Consolidated Financial Statements as of and for the three months ended September 26, 2020 and September 28, 2019 on December 7, 2020, the Company identified an error in the presentation of income taxes related to the allocation of the provision among interim periods prepared under US GAAP for the comparative period ended September 28, 2019. Accordingly, the amount previously presented for the three months ended September 28, 2019 was deemed to be an error. Following the identification of the error, the Company recorded an adjustment to recognize income taxes in the proper comparative interim period. The adjustment was deemed to be an error in previously issued financial statements under ASC 250, “ Accounting Changes and Error Corrections The following tables present the impacts of the adjustment on our previously issued financial statements as of and for the three months ended September 26, 2020 and September 28, 2019: Three Months Ended September 28, 2019 Previously As Reported Adjustment Corrected (unaudited) (unaudited) Revenue $ 39,669,996 $ - $ 39,669,996 Cost of Goods Sold 20,277,820 - 20,277,820 Gross Profit 19,392,176 - 19,392,176 Expenses: General and Administrative 54,094,949 - 54,094,949 Sales and Marketing 5,782,780 - 5,782,780 Depreciation and Amortization 9,484,181 - 9,484,181 Realized and Unrealized Loss on Changes in Fair Value of Contingent Consideration 2,284,054 - 2,284,054 Impairment Expense - - - Gain On Disposals of Assets, Restructuring Fees and Other Expenses (697,962 ) - (697,962 ) Total Expenses 70,948,002 - 70,948,002 Loss from Operations (51,555,826 ) - (51,555,826 ) Other Expense (Income): Interest Expense 8,163,617 - 8,163,617 Interest Income (369,342 ) - (369,342 ) Amortization of Debt Discount and Loan Origination Fees 3,067,535 - 3,067,535 Change in Fair Value of Derivatives (5,128,420 ) - (5,128,420 ) Realized and Unrealized Gain on Investments, Assets Held For Sale and Other Assets (11,480,322 ) - (11,480,322 ) Loss on Extinguishment of Debt 31,570,116 - 31,570,116 Total Other Expense 25,823,184 - 25,823,184 Loss from Continuing Operations Before Provision for Income Taxes (77,379,010 ) - (77,379,010 ) Provision for Income Tax (Expense) Benefit (6,020,522 ) 23,681,253 17,660,731 Net Loss from Continuing Operations (83,399,532 ) 23,681,253 (59,718,279 ) Net Loss from Discontinued Operations, Net of Taxes (3,855,053 ) 774,633 (3,080,420 ) Net Loss (87,254,585 ) 24,455,886 (62,798,699 ) Net Loss Attributable to Non-Controlling Interest (54,161,820 ) 15,585,890 (38,575,930 ) Net Loss Attributable to Shareholders of MedMen Enterprises Inc. $ (33,092,765 ) $ 8,869,996 $ (24,222,769 ) Loss Per Share - Basic and Diluted: From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. $ (0.15 ) $ 0.04 $ (0.11 ) From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. $ (0.02 ) $ 0.00 $ (0.02 ) Weighted-Average Shares Outstanding - Basic and Diluted 191,711,038 - 191,711,038 Three Months Ended September 28, 2019 Additional Accumulated TOTAL EQUITY ATTRIBUTABLE TO Non-Controlling TOTAL Paid-In Capital Deficit OF MEDMEN Interest EQUITY Previously Reported: BALANCE AS OF JUNE 30, 2019 $ 613,356,006 $ (370,382,824 ) $ 243,138,181 $ (31,867,405 ) $ 211,270,776 Net Loss - (33,092,765 ) (33,092,765 ) (54,161,820 ) (87,254,585 ) Controlling Interest Equity Transactions 78,636,466 (19,986,022 ) 58,650,444 (210,120 ) 58,440,324 Non-Controlling Interest Equity Transactions - - - (921,778 ) (921,778 ) BALANCE AS OF SEPTEMBER 28, 2019 $ 691,992,472 $ (423,461,611 ) $ 268,695,860 $ (87,161,123 ) $ 181,534,737 Adjustment Impacts: BALANCE AS OF JUNE 30, 2019 $ - $ - $ - $ - $ - Net Loss - 8,869,996 8,869,996 15,585,890 24,455,886 Controlling Interest Equity Transactions - - - - - Non-Controlling Interest Equity Transactions - - - - - BALANCE AS OF SEPTEMBER 28, 2019 $ - $ 8,869,996 $ 8,869,996 $ 15,585,890 $ 24,455,886 As Corrected: BALANCE AS OF JUNE 30, 2019 $ 613,356,006 $ (370,382,824 ) $ 243,138,181 $ (31,867,405 ) $ 211,270,776 Net Loss - (24,222,769 ) (24,222,769 ) (38,575,930 ) (62,798,699 ) Controlling Interest Equity Transactions 78,636,466 (19,986,022 ) 58,650,444 (210,120 ) 58,440,324 Non-Controlling Interest Equity Transactions - - - (921,778 ) (921,778 ) BALANCE AS OF SEPTEMBER 28, 2019 $ 691,992,472 $ (414,591,615 ) $ 277,565,856 $ (71,575,233 ) $ 205,990,623 Three Months Ended September 28, 2019 Previously As Reported Adjustment Corrected Net Loss from Continuing Operations $ (83,399,532 ) $ 23,681,253 $ (59,718,279 ) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: 43,348,526 - 43,348,526 Changes in Operating Assets and Liabilities: Income Taxes Receivable (2,994,072 ) 2,994,072 - Income Taxes Payable 11,242,233 (27,449,958 ) (16,207,725 ) Operating Assets and Liabilities (12,469,810 ) - (12,469,810 ) NET CASH USED IN CONTINUED OPERATING ACTIVITIES (44,272,655 ) (774,633 ) (45,047,288 ) Net Cash Provided by Discontinued Operating Activities 2,206,319 774,633 2,980,952 NET CASH USED IN OPERATING ACTIVITIES (42,066,336 ) - (42,066,336 ) NET CASH USED IN INVESTING ACTIVITIES (13,149,929 ) - (13,149,929 ) NET CASH PROVIDED BY FINANCING ACTIVITIES 63,698,694 - 63,698,694 NET INCREASE IN CASH AND CASH EQUIVALENTS 8,482,429 - 8,482,429 Cash and Cash Equivalents, Beginning of Period 33,753,747 - 33,753,747 CASH AND CASH EQUIVALENTS, END OF PERIOD $ 42,236,176 $ - $ 42,236,176 There was no effect on retained earnings or net assets in the unaudited interim Condensed Consolidated Balance Sheet as of September 26, 2020 as the provision for income taxes and retained earnings was properly recorded as of June 27, 2020. The impacts of the correction of error have been reflected throughout the financial statements, including the applicable footnotes, as appropriate.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Sep. 26, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Preparation	The accompanying unaudited interim Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). The unaudited interim Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the three months ended September 26, 2020, year ended June 27, 2020 and three months ended September 28, 2019, the consolidated results of operations and cash flows for the three months ended September 26, 2020 and September 28, 2019 have been included. The accompanying unaudited interim Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements, prepared in accordance with GAAP, have been condensed or omitted in accordance with SEC rules and regulations within the instruction to Form 10-Q and Article 10 of Regulation S-X. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in Item 13 of the registration statement on Form 10 for the fiscal year ended June 27, 2020.
Going Concern	As reflected in the Condensed Consolidated Financial Statements, the Company had an accumulated deficit and a negative net working capital (current liabilities greater than current assets) as of September 26, 2020, as well as a net loss and negative cash flow from operating activities for the reporting period then ended. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these unaudited interim Condensed Consolidated Financial Statements. Management believes that substantial doubt of our ability to meet our obligations for the next twelve months from the date these financial statements were first made available has been alleviated due to, but not limited to, (i) capital raised between December 2020 and December 2021, (ii) restructuring plans that have already been put in place to reduce corporate-level expenses, (iii) debt amendments that have been agreed to with lenders and landlords to defer cash interest and rent payments, (iv) reduction in capital expenditures through a slow-down in new store buildouts, (v) plans to divest non-core assets to raise non-dilutive capital, (vi) enhancements to its digital offering, including direct-to-consumer delivery and curbside pick-up in light of COVID-19 and (vii) a change in retail strategy to pass certain local taxes and payment processing fees to customers. However, management cannot provide any assurances that we will be successful in accomplishing any of our plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase our need to raise additional capital on an immediate basis. The Company will continually monitor its capital requirements based on its capital and operational needs and the economic environment and may raise new capital as necessary. The Company’s ability to continue as a going concern will depend on its ability to raise additional equity or debt in the private or public markets, reducing operating expenses, divesting of certain non-core assets, achieving cash flow profitability. While the Company has been successful in raising equity and debt to date, there can be no assurances that the Company will be successful in completing a financing in the future. If the Company is unable to raise additional capital whenever necessary, it may be forced to divest additional assets to raise capital and/or pay down its debt, amend its debt agreements which could potentially have a dilutive effect on the Company’s shareholders, further reduce operating expenses and temporarily pause the opening of new store locations. Furthermore, COVID-19 and the impact the global pandemic has had and will continue to have on the broader retail environment could also have a significant impact on the Company’s financial operations.
COVID-19	On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures worldwide. While the ultimate severity of the outbreak and its impact on the economic environment is uncertain, the Company is monitoring this closely. In the event that the Company were to experience widespread transmission of the virus at one or more of the Company’s store or other facilities, the Company could suffer reputational harm or other potential liability. Further, the Company’s business operations may be materially and adversely affected if a significant number of the Company’s employees are impacted by the virus.
Emerging Growth Company	The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”) under which emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.
Functional Currency	The Company and its subsidiaries’ functional currency, as determined by management, is the United States (“U.S.”) dollar. These unaudited interim Condensed Consolidated Financial Statements are presented in U.S. dollars as this is the primary economic environment of the group. All references to “C$” refer to Canadian dollars.
Significant Accounting Policies	The significant accounting policies and critical estimates applied by the Company in these unaudited interim Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in Item 13 of the registration statement on Form 10 for the fiscal year ended June 27, 2020.
Restricted Cash	Restricted cash balances are those which meet the definition of cash and cash equivalents but are not available for use by the Company. As of September 26, 2020 and June 27, 2020, restricted cash was $9,873 and $9,873, respectively, which is used to pay for lease costs and costs incurred related to building construction in Reno, Nevada. This account is managed by a contractor and the Company is required to maintain a certain minimum balance.
Down-Round Provisions	The Company calculates down-round features under ASU 2017-11, in which down round features do not meet the criteria for derivative accounting and no liability is to be recorded until an actual issuance of securities triggers the down-round feature.
Loss per Share	The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, DSU, RSU, warrants and stock options issued.
Recently Adopted Accounting Standards	In June 2016, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments” In January 2017, the FASB issued ASU No. 2017-04 “Intangibles— Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”
Recently Issued Accounting Standards	In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes”, which eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations. In January 2020, the FASB issued ASU 2020-01, “ Investments – Equity Securities (Topic 321) Investments – Equity Method and Joint Ventures (Topic 323) Derivatives and Hedging (Topic 815) In August 2020, the FASB issued ASU 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible instruments and contracts in an Entity’s Own Equity

INVENTORY (Tables)

INVENTORY (Tables)	3 Months Ended
	Sep. 26, 2020
INVENTORIES
Schedule of inventories	September 26, June 27, 2020 2020 Raw Materials $ 2,671,185 $ 2,055,500 Work-in-Process 9,654,494 8,807,137 Finished Goods 8,968,470 11,775,483 Total Inventory $ 21,294,149 $ 22,638,120

OTHER CURRENT ASSETS (Tables)

OTHER CURRENT ASSETS (Tables)	3 Months Ended
	Sep. 26, 2020
OTHER CURRENT ASSETS
Schedule of Other current assets	September 26, June 27, 2020 2020 Investments $ 3,036,791 $ 3,786,791 Excise Tax Receivable 3,447,005 5,254,595 Note Receivable 9,171,694 - Other Current Assets 113,429 64,071 Total Other Current Assets $ 15,768,919 $ 9,105,457
Schedule of Investments	ToroVerde Inc. The Hacienda Company, LLC Old Pal Other Investments TOTAL (1) (2) (3) Fair Value as of June 27, 2020 $ - $ 750,000 $ 1,970,000 $ 1,066,791 $ 3,786,791 Settlement of Liabilities - (750,000 ) - - (750,000 ) Fair Value as of September 26, 2020 $ - $ - $ 1,970,000 $ 1,066,791 $ 3,036,791

ASSETS HELD FOR SALE (Tables)

ASSETS HELD FOR SALE (Tables)	3 Months Ended
	Sep. 26, 2020
ASSETS HELD FOR SALE
Schedule of asset held for sale	PharmaCann Assets (1) Available for Sale Subsidiaries (2) Discontinued Operations TOTAL Balance at Beginning of Period $ 212,400 $ 12,066,428 $ 21,181,051 $ 33,459,879 Transferred In - 6,614,987 - 6,614,987 Gain on the Sale of Assets Held for Sale - 12,415,479 - 12,415,479 Proceeds from Sale - (19,407,879 ) - (19,407,879 ) Ongoing Activity from Discontinued Operations - (2,300,763 ) (477,657 ) (2,778,420 ) Balance at End of Period $ 212,400 $ 9,388,252 $ 20,703,394 $ 30,304,046
Schedule of discontinued operations	September 26, June 27, 2020 2020 Carrying Amounts of the Assets Included in Assets Held for Sale: Cash and Cash Equivalents $ 7,714 $ 743,271 Prepaid Expenses 4,054 7,798 Inventory - 520,464 Other Current Assets 53,176 81,427 TOTAL CURRENT ASSETS (1) Property and Equipment, Net 326,701 717,952 Operating Lease Right-of-Use Assets 1,042,535 190,986 Intangible Assets, Net 6,115,570 5,227,288 Goodwill 1,838,502 4,577,242 TOTAL NON-CURRENT ASSETS (1) TOTAL ASSETS OF SUBSIDIARIES CLASSIFIED AS HELD FOR SALE $ 9,388,252 $ 12,066,428 Carrying Amounts of the Liabilities Included in Assets Held for Sale: Accounts Payable and Accrued Liabilities $ 137,061 $ 963,255 Income Taxes Payable 85,616 159,053 Other Current Liabilities 2,670 27,854 Current Portion of Operating Lease Liabilities 274,079 - TOTAL CURRENT LIABILITIES (1) Operating Lease Liabilities, Net of Current Portion 1,088,221 296,694 Deferred Tax Liabilities 2,328,367 2,151,879 TOTAL NON-CURRENT LIABILITIES (1) - - TOTAL LIABILITIES OF SUBSIDIARIES CLASSIFIED AS HELD FOR SALE $ 3,916,014 $ 3,598,735

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Sep. 26, 2020
PROPERTY AND EQUIPMENT
Schedule of property and equipment	September 26, June 27, 2020 2020 Land and Buildings $ 37,421,326 $ 37,400,378 Finance Lease Right-of-Use Assets 12,556,847 26,194,566 Furniture and Fixtures 13,991,481 13,970,449 Leasehold Improvements 67,428,253 63,976,372 Equipment and Software 29,496,811 29,277,120 Construction in Progress 35,333,101 38,470,016 Total Property and Equipment 196,227,819 209,288,901 Less Accumulated Depreciation (40,030,274 ) (34,741,034 ) Property and Equipment, Net $ 156,197,545 $ 174,547,867

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Sep. 26, 2020
INTANGIBLE ASSETS
Schedule of Intangible assets	September 26, June 27, 2020 2020 Dispensary Licenses $ 133,053,216 $ 139,736,881 Customer Relationships 18,586,200 18,586,200 Management Agreement 7,594,937 7,594,937 Capitalized Software 9,311,278 9,255,026 Intellectual Property 8,520,116 8,520,121 Total Intangible Assets 177,065,747 183,693,165 Dispensary Licenses (21,228,281 ) (19,162,587 ) Customer Relationships (12,480,609 ) (8,113,913 ) Management Agreement (615,347 ) (565,972 ) Capitalized Software (2,862,569 ) (2,273,432 ) Intellectual Property (1,441,163 ) (5,496,231 ) Less Accumulated Amortization (38,627,969 ) (35,612,135 ) Intangible Assets, Net $ 138,437,778 $ 148,081,030

OTHER ASSETS (Tables)

OTHER ASSETS (Tables)	3 Months Ended
	Sep. 26, 2020
OTHER ASSETS
Schedule of Other assets	September 26, June 27, 2020 2020 Long-Term Security Deposits for Leases $ 9,270,225 $ 9,752,611 Loans and Other Long-Term Deposits 7,563,737 7,568,738 Other Assets 94,407 53,648 Total Other Assets $ 16,928,369 $ 17,374,997

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILTIES (Tables)	3 Months Ended
	Sep. 26, 2020
ACCOUNTS PAYABLE AND ACCRUED LIABILTIES
Schedule of accounts payable and accrued liabilities	September 26, June 27, 2020 2020 Accounts Payable $ 53,330,661 $ 58,614,619 Accrued Liabilities 9,998,881 10,532,715 Other Accrued Liabilities 12,937,196 10,383,596 Total Other Current Liabilities $ 76,266,738 $ 79,530,930

OTHER CURRENT LIABILITIES AND_2

OTHER CURRENT LIABILITIES AND OTHER NON-CURRENT LIABILITIES (Tables)	3 Months Ended
	Sep. 26, 2020
ACCOUNTS PAYABLE AND ACCRUED LIABILTIES
Schedule of other current liabilities	September 26, June 27, 2020 2020 Accrued Interest Payable $ 1,239,976 $ 9,051,650 Contingent Consideration 9,254,634 8,951,801 Derivatives 240,697 546,076 Other Current Liabilities 1,837,365 1,728,854 Total Other Current Liabilities $ 12,572,672 $ 20,278,381
Schedule of fair value of derivative liabilities	September 26, 2020 Balance as of Beginning of Year $ 546,076 Initial Recognition of Derivative Liabilities - Change in Fair Value of Derivative Liabilities (305,379 ) Balance as of End of Year $ 240,697

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Sep. 26, 2020
LEASES
Schedule of lease cost	September 26, September 28, 2020 2019 Finance Lease Cost: Amortization of Finance Lease Right-of-Use Assets $ 314,143 $ 2,070,767 Interest on Lease Liabilities 1,523,821 1,432,930 Operating Lease Cost 7,658,920 6,986,299 Total Lease Expenses $ 9,496,884 $ 10,489,996 2020 2019 (Gain) and Loss on Sale and Leaseback Transactions, Net $ - $ (704,207 ) Cash Paid for Amounts Included in the Measurement of Lease Liabilities: Financing Cash Flows from Finance Leases $ 39,879 $ - Operating Cash Flows from Operating Leases $ 9,158,398 $ 7,172,043 Non-Cash Additions to Right-of-Use Assets and Lease Liabilities: Recognition of Right-of-Use Assets for Finance Leases $ 350,249 $ 42,676,528 Recognition of Right-of-Use Assets for Operating Leases $ - $ 141,557,231 2020 2019 Weighted-Average Remaining Lease Term (Years) - Finance Leases 38 48 Weighted-Average Remaining Lease Term (Years) - Operating Leases 8 9 Weighted-Average Discount Rate - Finance Leases 16.22 % 10.66 % Weighted-Average Discount Rate - Operating Leases 13.50 % 11.35 %
Schedule of Future lease payments	Fiscal Year Ending Operating Leases Finance Leases June 26, 2021 $ 23,512,450 $ 3,725,785 June 25, 2022 31,430,045 5,860,696 June 24, 2023 31,536,071 6,035,912 June 29, 2024 41,208,860 11,494,331 June 28, 2025 38,674,115 7,347,736 September 26, 2026 and Thereafter 126,851,773 1,080,067,137 Total Lease Payments 293,213,314 1,114,531,597 Less: Interest (169,709,464 ) (1,083,412,254 ) Present Value of Lease Liability $ 123,503,850 $ 31,119,343

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
	Sep. 26, 2020
NOTES PAYABLE
Schedule of notes payable	September 26, June 27, 2020 2020 Finance liabilities incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum. $ 83,576,661 $ 83,576,661 Non-revolving, senior secured term notes dated between October 1, 2018 and September 16, 2020, issued to accredited investors, which mature on January 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum. 89,464,671 77,675,000 Convertible debentures dated September 16, 2020, issued to accredited investors and qualified institutional buyers, which mature on September 16, 2022, and bear interest at a rate of 7.5% 1,000,000 - Promissory notes dated between January 15, 2019 through March 29, 2019, issued for deferred payments on acquisitions, which mature on varying dates from August 3, 2019 to June 30, 2020 and bear interest at rates ranging from 8.0% to 9.0% per annum. 16,298,250 16,173,250 Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471. 2,057,058 2,339,564 Other 15,419 15,418 Total Notes Payable 192,412,059 179,779,893 Less Unamortized Debt Issuance Costs and Loan Origination Fees (12,369,731 ) (10,781,288 ) Net Amount $ 180,042,328 $ 168,998,605 Less Current Portion of Notes Payable (17,067,303 ) (16,188,668 ) Notes Payable, Net of Current Portion $ 162,975,025 $ 152,809,937
Schedule of reconciliation notes payable	September 26, 2020 Balance at Beginning of Period $ 168,998,605 Cash Additions 4,125,000 Non-Cash Addition - Debt Modification 877,439 Debt Discount Recognized on Modification (879,267 ) Paid-In-Kind Interest Capitalized 7,912,232 Cash Payments (284,334 ) Equity Component of Debt (2,883,786 ) Cash Paid for Debt Issuance Costs 1,828 Accretion of Debt Discount 2,174,611 Balance at End of Period $ 180,042,328 Less Current Portion of Notes Payable (17,067,303 ) Notes Payable, Net of Current Portion $ 162,975,025

SENIOR SECURED CONVERTIBLE CR_2

SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Tables)	3 Months Ended
	Sep. 26, 2020
SENIOR SECURED CONVERTIBLE CREDIT FACILITY
Schedule of senior secured convertible credit facility	September 26, June 27, Tranche 2020 2020 Senior secured convertible notes dated April 23, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 1A $ 22,613,719 $ 21,660,583 Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 1B 89,839,938 86,053,316 Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 2 27,740,154 26,570,948 Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 3 10,741,556 10,288,815 Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 4 13,050,118 12,500,000 Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 20,278,293 19,423,593 Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. IA-1 2,835,875 2,734,282 Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. IA-2 5,484,058 - Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 8,560,735 8,199,863 Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 2,040,906 - Total Drawn on Senior Secured Convertible Credit Facility 203,185,352 187,431,400 Less Unamortized Debt Discount (33,810,741 ) (21,062,937 ) Senior Secured Convertible Credit Facility, Net $ 169,374,611 $ 166,368,463
Schedule of reconciliation senior secured convertible credit facilty	Tranche 1 Tranche 2 Tranche 3 Tranche 4 Amendment Fee Notes Restatement Fee Notes 2nd Restatement Fee Notes TOTAL Balance as of June 27, 2020 $ 102,833,447 $ 25,352,687 $ 9,680,433 $ 2,455,231 $ 18,964,600 $ 7,082,065 $ - $ 166,368,463 Cash Additions - - - 4,825,000 - - - 4,825,000 Fees Capitalized to Debt Related to - - - 468,568 - - 2,000,000 2,468,568 Paid-In-Kind Interest Capitalized 4,739,758 1,169,206 452,741 667,205 854,700 360,872 40,906 8,285,388 Net Effect on Equity Component of New (5,440,833 ) (1,492,268 ) (586,606 ) (2,618,335 ) (1,193,896 ) (2,444,153 ) - (13,776,091 ) Cash Paid for Debt Issuance Costs - - - 175,000 - - - 175,000 Amortization of Debt Discounts 261,193 73,947 31,097 585,518 28,685 47,843 - 1,028,283 Balance as of September 26, 2020 $ 102,393,565 $ 25,103,572 $ 9,577,665 $ 6,558,187 $ 18,654,089 $ 5,046,627 $ 2,040,906 $ 169,374,611

SHAREHOLDERS EQUITY (Tables)

SHAREHOLDERS EQUITY (Tables)	3 Months Ended
	Sep. 26, 2020
MEZZANINE EQUITY
Schedule of Shares issued and outstanding	Subordinate Voting Shares Super Voting Shares MM CAN USA Class B Redeemable Units MM Enterprises USA Common Units Balance as of June 27, 2020 403,907,218 815,295 236,123,851 725,016 Shares Issued to Settle Accounts Payable and Liabilities 3,608,690 - - - Redemption of MedMen Corp Redeemable Shares 29,947,959 - (29,947,959 ) - Shares Issued for Vested Restricted Stock Units 614,207 - - - Stock Grants for Compensation 1,318,865 - - - Balance as of September 26, 2020 439,396,939 815,295 206,175,892 725,016
Schedule of VIE	Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 912,450 $ (4,268,671 ) $ 5,913,332 $ 2,557,111 Non-Current Assets 13,890,323 3,188,194 5,011,523 22,090,040 Total Assets 14,802,773 (1,080,477 ) 10,924,855 24,647,151 Current Liabilities $ 12,471,726 $ 3,142,212 $ 1,895,769 $ 17,509,707 Non-Current Liabilities 9,142,143 2,611,035 1,146,331 12,899,509 Total Liabilities 21,613,869 5,753,247 3,042,100 30,409,216 Non-Controlling Interest $ (6,811,096 ) $ (6,833,724 ) $ 7,882,755 $ (5,762,065 ) Revenues $ 2,245,915 $ (570 ) $ 3,438,820 $ 5,684,165 Net (Loss) Income Attributable to Non-Controlling Interest $ (885,911 ) $ (763,397 ) $ 1,103,128 $ (546,180 ) As of and for the year ended June 27, 2020, the balances of the VIEs consists of the following: Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 1,233,188 $ 811,025 $ 6,639,231 $ 8,683,444 Non-Current Assets 16,867,824 3,259,563 5,032,428 25,159,815 Total Assets 18,101,012 4,070,588 11,671,659 33,843,259 Current Liabilities $ 12,831,161 $ 7,481,953 $ 3,745,710 $ 24,058,824 Non-Current Liabilities 11,196,585 2,662,078 1,146,322 15,004,985 Total Liabilities 24,027,746 10,144,031 4,892,032 39,063,809 Non-Controlling Interest $ (5,926,734 ) $ (6,073,443 ) $ 6,779,627 $ (5,220,550 ) Revenues $ 10,949,458 $ - $ 13,976,810 $ 24,926,268 Net (Loss) Income Attributable to Non-Controlling Interest $ (6,132,528 ) $ (3,777,079 ) $ 3,143,437 $ (6,766,170 )
Schedule of other non-controlling interest	Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. Other Non- Controlling Interests TOTAL Balance as of June 27, 2020 $ (5,925,185 ) $ (6,070,327 ) $ 6,779,627 $ (331,561,812 ) $ (336,777,697 ) Net Income (Loss) (885,911 ) (763,397 ) 1,103,128 (10,381,361 ) (10,927,541 ) Equity Component on Debt and Debt Modification - - - 2,485,588 2,485,588 Redemption of MedMen Corp Redeemable Shares - - - (14,370,838 ) (14,370,838 ) Balance as of September 26, 2020 $ (6,811,096 ) $ (6,833,724 ) $ 7,882,755 $ (353,828,423 ) $ (359,590,488 )

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Sep. 26, 2020
SHARE-BASED COMPENSATION
Schedule of share-based compensation expense	Three Months Ended September 26, September 28, 2020 2019 Stock Options $ 1,008,538 $ 1,687,273 LTIP Units - 833,531 Stock Grants for Services 181,589 364,948 Restricted Stock Grants 157,477 1,680,625 Total Share-Based Compensation $ 1,347,604 $ 4,566,377
Schedule of stock options	Number of Stock Options Weighted-Average Exercise Price Number of Stock Options Exercisable Weighted-Average Exercise Price Balance as of June 27, 2020 8,618,204 $ 2.78 4,248,393 $ 2.78 Granted - $ - 896,857 $ 3.48 Forfeited (717,794 ) $ (3.26 ) - $ - Balance as of September 26, 2020 7,900,410 $ 2.74 5,145,250 $ 3.24
Schedule of LTIP Units and LLC Redeemable Units	Weighted LTIP Units LLC Average Issued and Redeemable Grant Date Outstanding Units Fair Value Balance as of June 27, 2020 and September 26, 2020 19,323,878 725,016 $ 0.52
Schedule of Deferred Stock Units	Issued and Outstanding Weighted- Average Fair Value Balance as of June 27, 2020 1,283,567 $ 0.38 Granted - $ - Balance as of September 26, 2020 1,283,567 $ 0.38
Schedule of Restricted Stock Grants	Issued and Outstanding Vested Weighted- Average Fair Value Balance as of June 27, 2020 7,159,164 192,459 $ 0.68 Granted 614,207 - $ 0.29 Redemption of Vested Stock (614,207 ) (614,207 ) $ 0.29 Vesting of Restricted Stock - 628,873 $ 0.35 Balance as of September 26, 2020 7,159,164 207,125 $ 0.68
Schedule of Warrants	Number of Warrants Outstanding Subordinate Voting Shares MedMen Corp Redeemable Shares Total Weighted-Average Exercise Price Balance as of June 27, 2020 114,998,915 40,455,731 155,454,646 $ 0.59 Issued 110,757,575 70,455,726 181,213,301 $ 0.17 Cancelled (1,080,226 ) (40,455,731 ) (41,535,957 ) $ (0.50 ) Balance as of September 26, 2020 224,676,264 70,455,726 295,131,990 $ 0.34
Schedule of Black-Scholes option-pricing model	September 26, June 27 2020 2020 Weighted-Average Risk-Free Annual Interest Rate 0.12 % 2.82 % Weighted-Average Expected Annual Dividend Yield 0 % 0 % Weighted-Average Expected Stock Price Volatility 91.38 % 82.93 % Weighted-Average Expected Life of Warrants 1 year 1 year
Schedule of fair value of warrants	Weighted-Average Risk-Free Annual Interest Rate 0.08 % Weighted-Average Expected Annual Dividend Yield 0 % Weighted-Average Expected Stock Price Volatility 52.84 % Weighted-Average Expected Life of Warrants 0.6 year

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	3 Months Ended
	Sep. 26, 2020
LOSS PER SHARE
Schedule of basic and diluted loss per share	Three Months Ended September 26, September 28, 2020 2019 Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. $ (19,237,687 ) $ (21,142,349 ) Less: Deemed Dividend - Down Round Feature of Warrants (4,883,467 ) - Net Loss from Continuing Operations Available to Shareholders of MedMen Enterprises, Inc. $ (24,121,154 ) $ (21,142,349 ) Net Loss from Discontinued Operations (2,682,175 ) (3,080,420 ) Weighted-Average Number of Shares Outstanding 423,187,218 191,711,038 Earnings (Loss) Per Share - Basic and Diluted: From Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. $ (0.06 ) $ (0.11 ) From Discontinued Operations $ (0.01 ) $ (0.02 )

GENERAL AND ADMINISTRATIVE EX_2

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)	3 Months Ended
	Sep. 26, 2020
GENERAL AND ADMINISTRATIVE EXPENSES
Schedule of general and administrative expenses	September 26, 2020 September 28, 2019 Salaries and Benefits $ 10,040,704 $ 20,901,335 Professional Fees 3,599,335 5,285,269 Rent 8,607,733 7,134,515 Licenses, Fees and Taxes 3,250,878 2,321,899 Other General and Administrative 6,184,954 18,451,931 Total General and Administrative Expenses $ 31,683,604 $ 54,094,949

PROVISION FOR INCOME TAXES AN_2

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Tables)	3 Months Ended
	Sep. 26, 2020
PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES
Schedule of income tax expense and effective tax rates	Three Months Ended September 26, 2020 September 28, 2019 Loss from Continuing Operations Before Provision for Income Taxes $ (19,826,666 ) $ (77,379,010 ) Income Tax (Expense) Benefit (10,338,562 ) 17,660,731 Effective Tax Rate (52.04 )% (22.82) %

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	3 Months Ended
	Sep. 26, 2020
RELATED PARTY TRANSACTIONS
Schedule of Related party transacrions	As of September 26, 2020 and June 27, 2020, amounts due from related parties were as follows: September 26, June 27, Name and Relationship to Company Transaction 2020 2020 MMOF GP II, LLC (“Fund LP II”), an entity which Mr. Adam Bierman, Mr. Andrew Modlin and Mr. Christopher Ganan each holds 33.3% indirect voting interest. The shareholders each hold 27.1% of indirect equity interest in Fund LP II, the General Partner of Fund II, which both hold equity interests in a subsidiary of the Company. (1) Management Fees $ 1,820,204 $ 1,820,204 MedMen Opportunity Fund GP, LLC (“Fund LP”), an entity which Mr. Adam Bierman, Mr. Andrew Modlin and Mr. Christopher Ganan each holds 33.3% indirect voting interest. The shareholders each hold 24.2% of indirect equity interest in Fund LP, the General Partner of Fund I, which both hold equity interests in a subsidiary of the Company. (1) Management Fees 1,289,514 1,289,513 Total Amounts Due from Related Parties $ 3,109,718 $ 3,109,717 _____________________ (1) As of February 2020 and May 2020, Mr. Adam Bierman and Mr. Andrew Modlin, respectively, no longer held board or management positions and therefore as of September 26, 2020 are not related parties, however they were during the fiscal year ended June 27, 2020. As of September 26, 2020, Chris Ganan is a member of the Company’s board of directors and thus considered a related party under ASC 850, “Related Party Disclosures”. As of September 26, 2020 and June 27, 2020, amounts due to related parties were as follows: September 26, June 27, Name and Relationship to Company Transaction 2020 2020 Fund LP II, an entity which Mr. Adam Bierman, Mr. Andrew Modlin and Mr. Christopher Ganan each holds 33.3% indirect voting interest. The shareholders each hold 27.1% of indirect equity interest in Fund LP II, the General Partner of Fund II, which both hold equity interests in a subsidiary of the Company. (1) Working Capital, Construction and Tenant Improvements, Lease Deposits and Cash Used for Acquisitions $ (1,093,896 ) $ (1,093,896 ) Fund LP, an entity which Mr. Adam Bierman, Mr. Andrew Modlin and Mr. Christopher Ganan each holds 33.3% indirect voting interest. The shareholders each hold 24.2% of indirect equity interest in Fund LP, the General Partner of Fund I, which both hold equity interests in a subsidiary of the Company. (1) Working Capital, Management Fees and Cash Used for Acquisitions (1,986,697 ) (1,986,697 ) Other (1,473,122 ) (1,476,221 ) Total Amounts Due to Related Parties $ (4,553,715 ) $ (4,556,814 ) _____________________ (1) As of February 2020 and May 2020, Mr. Adam Bierman and Mr. Andrew Modlin, respectively, no longer held board or management positions and therefore as of September 26, 2020 are not related parties, however they were during the fiscal year ended June 27, 2020. As of September 26, 2020, Chris Ganan is a member of the Company’s board of directors and thus considered a related party under ASC 850, “Related Party Disclosures”.

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	3 Months Ended
	Sep. 26, 2020
DISCONTINUED OPERATIONS
Schedule of net operating loss of discontinued operation	September 26, September 28, 2020 2019 Revenue $ 1,599,990 $ 4,304,749 Cost of Goods Sold 1,268,752 3,880,606 Gross Profit 331,238 424,143 Expenses: General and Administrative 976,611 1,823,752 Sales and Marketing 6,501 948 Depreciation and Amortization 49,142 499,328 Total Expenses 1,032,254 2,324,028 Income (Loss) from Operations (701,016 ) (1,899,885 ) Other Expense (Income): Other Expense 37,056 5,385 Total Other Expense 37,056 5,385 Loss on Discontinued Operations Before Provision for Income Taxes (738,072 ) (1,905,270 ) Provision for Income Tax (Expense) Benefit (1,944,103 ) (1,175,150 ) Loss on Discontinued Operations $ (2,682,175 ) $ (3,080,420 )
Schedule of assets included in discontinued operation	September 26, June 27, 2020 2020 Carrying Amounts of the Assets Included in Discontinued Operations: Cash and Cash Equivalents $ 319,834 $ 522,966 Accounts Receivable 239,702 274,886 Prepaid Expenses 59,921 74,622 Inventory 3,241,697 3,323,978 Other Current Assets 65,851 64,600 TOTAL CURRENT ASSETS (1) Property and Equipment, Net 4,224,082 4,288,808 Operating Lease Right-of-Use Assets 5,136,228 5,257,327 Intangible Assets, Net 7,298,804 7,260,288 Other Assets 117,275 113,576 TOTAL NON-CURRENT ASSETS (1) TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 20,703,394 $ 21,181,051 Carrying Amounts of the Liabilities Included in Discontinued Operations: Accounts Payable and Accrued Liabilities $ 1,732,280 $ 2,126,162 Income Taxes Payable 2,818,170 946,679 Other Current Liabilities 22,462 22,747 Current Portion of Operating Lease Liabilities 379,529 385,699 TOTAL CURRENT LIABILITIES (1) Operating Lease Liabilities, Net of Current Portion 5,199,132 5,300,936 Deferred Tax Liabilities 6,278,078 6,278,079 TOTAL NON-CURRENT LIABILITIES (1) TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 16,429,651 $ 15,060,302

CORRECTION OF ERROR IN PREVIO_2

CORRECTION OF ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Table)	3 Months Ended
	Sep. 26, 2020
Summary of financial statement	Three Months Ended September 28, 2019 Previously As Reported Adjustment Corrected (unaudited) (unaudited) Revenue $ 39,669,996 $ - $ 39,669,996 Cost of Goods Sold 20,277,820 - 20,277,820 Gross Profit 19,392,176 - 19,392,176 Expenses: General and Administrative 54,094,949 - 54,094,949 Sales and Marketing 5,782,780 - 5,782,780 Depreciation and Amortization 9,484,181 - 9,484,181 Realized and Unrealized Loss on Changes in Fair Value of Contingent Consideration 2,284,054 - 2,284,054 Impairment Expense - - - Gain On Disposals of Assets, Restructuring Fees and Other Expenses (697,962 ) - (697,962 ) Total Expenses 70,948,002 - 70,948,002 Loss from Operations (51,555,826 ) - (51,555,826 ) Other Expense (Income): Interest Expense 8,163,617 - 8,163,617 Interest Income (369,342 ) - (369,342 ) Amortization of Debt Discount and Loan Origination Fees 3,067,535 - 3,067,535 Change in Fair Value of Derivatives (5,128,420 ) - (5,128,420 ) Realized and Unrealized Gain on Investments, Assets Held For Sale and Other Assets (11,480,322 ) - (11,480,322 ) Loss on Extinguishment of Debt 31,570,116 - 31,570,116 Total Other Expense 25,823,184 - 25,823,184 Loss from Continuing Operations Before Provision for Income Taxes (77,379,010 ) - (77,379,010 ) Provision for Income Tax (Expense) Benefit (6,020,522 ) 23,681,253 17,660,731 Net Loss from Continuing Operations (83,399,532 ) 23,681,253 (59,718,279 ) Net Loss from Discontinued Operations, Net of Taxes (3,855,053 ) 774,633 (3,080,420 ) Net Loss (87,254,585 ) 24,455,886 (62,798,699 ) Net Loss Attributable to Non-Controlling Interest (54,161,820 ) 15,585,890 (38,575,930 ) Net Loss Attributable to Shareholders of MedMen Enterprises Inc. $ (33,092,765 ) $ 8,869,996 $ (24,222,769 ) Loss Per Share - Basic and Diluted: From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. $ (0.15 ) $ 0.04 $ (0.11 ) From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. $ (0.02 ) $ 0.00 $ (0.02 ) Weighted-Average Shares Outstanding - Basic and Diluted 191,711,038 - 191,711,038 Three Months Ended September 28, 2019 Additional Accumulated TOTAL EQUITY ATTRIBUTABLE TO Non-Controlling TOTAL Paid-In Capital Deficit OF MEDMEN Interest EQUITY Previously Reported: BALANCE AS OF JUNE 30, 2019 $ 613,356,006 $ (370,382,824 ) $ 243,138,181 $ (31,867,405 ) $ 211,270,776 Net Loss - (33,092,765 ) (33,092,765 ) (54,161,820 ) (87,254,585 ) Controlling Interest Equity Transactions 78,636,466 (19,986,022 ) 58,650,444 (210,120 ) 58,440,324 Non-Controlling Interest Equity Transactions - - - (921,778 ) (921,778 ) BALANCE AS OF SEPTEMBER 28, 2019 $ 691,992,472 $ (423,461,611 ) $ 268,695,860 $ (87,161,123 ) $ 181,534,737 Adjustment Impacts: BALANCE AS OF JUNE 30, 2019 $ - $ - $ - $ - $ - Net Loss - 8,869,996 8,869,996 15,585,890 24,455,886 Controlling Interest Equity Transactions - - - - - Non-Controlling Interest Equity Transactions - - - - - BALANCE AS OF SEPTEMBER 28, 2019 $ - $ 8,869,996 $ 8,869,996 $ 15,585,890 $ 24,455,886 As Corrected: BALANCE AS OF JUNE 30, 2019 $ 613,356,006 $ (370,382,824 ) $ 243,138,181 $ (31,867,405 ) $ 211,270,776 Net Loss - (24,222,769 ) (24,222,769 ) (38,575,930 ) (62,798,699 ) Controlling Interest Equity Transactions 78,636,466 (19,986,022 ) 58,650,444 (210,120 ) 58,440,324 Non-Controlling Interest Equity Transactions - - - (921,778 ) (921,778 ) BALANCE AS OF SEPTEMBER 28, 2019 $ 691,992,472 $ (414,591,615 ) $ 277,565,856 $ (71,575,233 ) $ 205,990,623 Three Months Ended September 28, 2019 Previously As Reported Adjustment Corrected Net Loss from Continuing Operations $ (83,399,532 ) $ 23,681,253 $ (59,718,279 ) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: 43,348,526 - 43,348,526 Changes in Operating Assets and Liabilities: Income Taxes Receivable (2,994,072 ) 2,994,072 - Income Taxes Payable 11,242,233 (27,449,958 ) (16,207,725 ) Operating Assets and Liabilities (12,469,810 ) - (12,469,810 ) NET CASH USED IN CONTINUED OPERATING ACTIVITIES (44,272,655 ) (774,633 ) (45,047,288 ) Net Cash Provided by Discontinued Operating Activities 2,206,319 774,633 2,980,952 NET CASH USED IN OPERATING ACTIVITIES (42,066,336 ) - (42,066,336 ) NET CASH USED IN INVESTING ACTIVITIES (13,149,929 ) - (13,149,929 ) NET CASH PROVIDED BY FINANCING ACTIVITIES 63,698,694 - 63,698,694 NET INCREASE IN CASH AND CASH EQUIVALENTS 8,482,429 - 8,482,429 Cash and Cash Equivalents, Beginning of Period 33,753,747 - 33,753,747 CASH AND CASH EQUIVALENTS, END OF PERIOD $ 42,236,176 $ - $ 42,236,176

NATURE OF OPERATIONS (Details N

NATURE OF OPERATIONS (Details Narrative)	Jan. 24, 2018shares
MM Enterprises USA Class B Units [Member]
Shares received	217,184,382

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Restricted cash	$ 9,873	$ 9,873

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Total Inventory	$ 21,294,149	$ 22,638,120
Inventory [Member]
Raw Materials	2,671,185	2,055,500
Work-in-Process	9,654,494	8,807,137
Finished Goods	8,968,470	11,775,483
Total Inventory	$ 21,294,149	$ 22,638,120

OTHER CURRENT ASSETS (Details)

OTHER CURRENT ASSETS (Details) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Other Current Assets	$ 15,768,919	$ 9,105,457
Other Current Assets [Member]
Investments	3,036,791	3,786,791
Excise Tax Receivable	3,447,005	5,254,595
Notes Receivable	9,171,694	0
Other Current Assets	113,429	64,071
Total Other Current Assets	$ 15,768,919	$ 9,105,457

OTHER CURRENT ASSETS (Details 1

OTHER CURRENT ASSETS (Details 1)	3 Months Ended
	Sep. 26, 2020USD ($)
Total [Member]
Fair value beginning balance	$ 3,786,791
Settlement of Liabilities	(750,000)
Fair value evening balance	3,036,791
Other Investments [Member]
Fair value beginning balance	1,066,791
Settlement of Liabilities	0
Fair value evening balance	1,066,791
Old Pal [Member]
Fair value beginning balance	1,970,000
Settlement of Liabilities	0
Fair value evening balance	1,970,000
The Hacienda Company LLC [Member]
Fair value beginning balance	750,000
Settlement of Liabilities	(750,000)
Fair value evening balance	0
ToroVerde Inc [Member]
Fair value beginning balance	0
Settlement of Liabilities	0
Fair value evening balance	$ 0

OTHER CURRENT ASSETS (Details N

OTHER CURRENT ASSETS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jul. 31, 2018	Sep. 26, 2020	Jun. 27, 2020
Equity ownership percentages		2.60%
Voting interests percentages		1.40%
Old Pal [Member]
Fair Value of investment		$ 1,970,000
Old Pal [Member] | October 2018 and March 2019 [Member]
Voting interests percentages		8.70%
Aggregate purchase price		$ 2,000,000
Outstanding units percentages		10.00%
ToroVerde Inc [Member]
Equity ownership percentages		14.30%	14.30%
Voting interests percentages		14.30%	14.30%
Aggregate purchase price	$ 5,000,000
Common shares purchased	9,000,000
Common shares purchase price per share	$ 0.56
Percentages of outstanding common shares	14.30%
The Hacienda Company LLC [Member]
Equity ownership percentages		3.20%	0.00%
Voting interests percentages		3.20%	0.00%
Aggregate purchase price	$ 1,500,000
Settlement of outstanding balances		$ 750,000

ASSETS HELD FOR SALE (Details)

ASSETS HELD FOR SALE (Details)	3 Months Ended
	Sep. 26, 2020USD ($)
Balance at End of Period	$ 30,304,046
Pharma Cann Assets [Member]
Balance at Beginning of Period	212,400
Transferred In	0
Gain on the Sale of Assets Held for Sale	0
Proceeds from Sale	0
Ongoing Activity from Discontinued Operations	0
Balance at End of Period	212,400
Discontinued Operations [Member]
Balance at Beginning of Period	21,181,051
Transferred In	0
Gain on the Sale of Assets Held for Sale	0
Proceeds from Sale	0
Ongoing Activity from Discontinued Operations	(477,657)
Balance at End of Period	20,703,394
Available For Sale Subsidiaries [Member]
Balance at Beginning of Period	12,066,428
Transferred In	6,614,987
Gain on the Sale of Assets Held for Sale	12,415,479
Proceeds from Sale	(19,407,879)
Ongoing Activity from Discontinued Operations	(2,300,763)
Balance at End of Period	9,388,252
Total [Member]
Balance at Beginning of Period	33,459,879
Transferred In	6,614,987
Gain on the Sale of Assets Held for Sale	12,415,479
Proceeds from Sale	(19,407,879)
Ongoing Activity from Discontinued Operations	(2,778,420)
Balance at End of Period	$ 30,304,046

ASSETS HELD FOR SALE (Details 1

ASSETS HELD FOR SALE (Details 1) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Carrying Amount of the Assets Included in Assets Held for Sale
Cash and Cash Equivalaent	$ 10,310,260	$ 10,093,925
Other Current Assets	15,768,919	9,105,457
TOTAL CURRENT ASSETS
Property and Equipment, Net	156,197,545	174,547,867
Operating Lease Right-of-use Assets	100,762,121	116,354,828
Goodwill	33,861,150	33,861,150
TOTAL NON-CURRENT ASSETS
TOTAL ASSETS OF SUBSIDIARIES CLASSIFIED AS HELD FOR SALE	534,176,277	574,263,604
Carrying Amount of the Liabilities in Assets held for Sale
Other Current Liabilities	12,572,672	20,278,381
Current Portion of Operating Lease Liabilities	8,206,432	9,757,669
TOTAL CURRENT LIABILITIES
Operating Lease Liabilities, Net of Current Portion	115,297,418	131,045,238
TOTAL NON-CURRENT LIABILITIES
TOTAL LIABILITIES OF SUBSIDIARIES CLASSIFIED AS ASSETS HELD FOR SALE	726,512,870	751,152,054
Assets Held For Sale [Member]
Carrying Amount of the Assets Included in Assets Held for Sale
Cash and Cash Equivalaent	7,714	743,271
Prepaid Expenses	4,054	7,798
Inventory	0	520,464
Other Current Assets	53,176	81,427
TOTAL CURRENT ASSETS
Property and Equipment, Net	326,701	717,952
Operating Lease Right-of-use Assets	1,042,535	190,986
Intangible Assets, Net	6,115,570	5,227,288
Goodwill	1,838,502	4,577,242
TOTAL NON-CURRENT ASSETS
TOTAL ASSETS OF SUBSIDIARIES CLASSIFIED AS HELD FOR SALE	9,388,252	12,066,428
Carrying Amount of the Liabilities in Assets held for Sale
Account Payable and Accrued Liabilities	137,061	963,255
Income Taxes Payable	85,616	159,053
Other Current Liabilities	2,670	27,854
Current Portion of Operating Lease Liabilities	274,079	0
TOTAL CURRENT LIABILITIES
Operating Lease Liabilities, Net of Current Portion	1,088,221	296,694
Deffered Tax liabilities	2,328,367	2,151,879
TOTAL NON-CURRENT LIABILITIES
TOTAL LIABILITIES OF SUBSIDIARIES CLASSIFIED AS ASSETS HELD FOR SALE	$ 3,916,014	$ 3,598,735

ASSETS HELD FOR SALE (Details N

ASSETS HELD FOR SALE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Nov. 16, 2020	Sep. 26, 2020	Jun. 26, 2020	Sep. 27, 2020	Jun. 27, 2020
Carrying Amount of the Assets Included in Assets Held for Sale
Membership interests		2.60%
July 1, 2020 [Member]
Carrying Amount of the Assets Included in Assets Held for Sale
Consideration		$ 20,000,000
Cash received		10,000,000
Additional Cash	$ 8,000,000
Secured promissory note		$ 2,000,000
MME Evanston Retail, LLC [Member]
Carrying Amount of the Assets Included in Assets Held for Sale
Membership interests				100.00%
Staunton [Member]
Carrying Amount of the Assets Included in Assets Held for Sale
Membership interests					100.00%
Separate Agreements [Member]
Carrying Amount of the Assets Included in Assets Held for Sale
Membership interests		100.00%
Impairment charges		$ 789,709
Carrying amount		$ 212,400
Aggregate sale price			$ 5,250,000
Agreement Description		Non-binding term sheet was entered on June 26, 2020 and $750,000 is to be paid upon the date of close in addition to $750,000 paid in equal monthly installments over twelve months through a promissory note. An additional verbal agreement was entered into during the three months ended September 26, 2020, in which the total consideration to be paid includes $3,500,000 cash paid within thirty days following the date of close and equity consideration equal to $250,000.

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Property and Equipment, Net	$ 156,197,545	$ 174,547,867
Property And Equipment [Member]
Land and Buildings	37,421,326	37,400,378
Finance Lease Right-of-Use Assets	12,556,847	26,194,566
Furnitures and Fixtures	13,991,481	13,970,449
Leasehold improvements	67,428,253	63,976,372
Equipment and Software	29,496,811	29,277,120
Construction in Progress	35,333,101	38,470,016
Total Property and Equipment	196,227,819	209,288,901
Less Accumulated Depreciation	(40,030,274)	(34,741,034)
Property and Equipment, Net	$ 156,197,545	$ 174,547,867

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
INTANGIBLE ASSETS
Depreciation Expense	$ 5,335,301	$ 7,034,650
Cost of Good Sold	62,447	942,542
Right of use assets	604,280	2,070,767
Borrowing costs	$ 0	$ 876,096
Average capitalization rate	0.00%	8.80%
Labor related costs	$ 60,620	$ 436,164
Share-based compensation	$ 8,154	$ 136,386

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Total Intangible Assets	$ 177,065,747	$ 183,693,165
Less Accumulated Amortization	(38,627,969)	(35,612,135)
Intangible Assets, Net	138,437,778	148,081,030
Capitalized Software [Member]
Less Accumulated Amortization	(2,862,569)	(2,273,432)
Intangible Assets, Net	9,311,278	9,255,026
Management Agreement [Member]
Less Accumulated Amortization	(615,347)	(565,972)
Intangible Assets, Net	7,594,937	7,594,937
Dispensary License [Member]
Less Accumulated Amortization	(21,228,281)	(19,162,587)
Intangible Assets, Net	133,053,216	139,736,881
Customer Relationship [Member]
Less Accumulated Amortization	(12,480,609)	(8,113,913)
Intangible Assets, Net	18,586,200	18,586,200
Intellectual Property [Member]
Less Accumulated Amortization	(1,441,163)	(5,496,231)
Intangible Assets, Net	$ 8,520,116	$ 8,520,121

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
INTANGIBLE ASSETS
Amortization expense	$ 3,352,854	$ 3,359,970
Share based compensation	$ 24,819	$ 201,254

OTHER ASSETS (Details)

OTHER ASSETS (Details) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Other Current Assets	$ 15,768,919	$ 9,105,457
Other Assets [Member]
Long-Term Security Diposits for Leases	9,270,225	9,752,611
Loans and Other Long-Term Diposits	7,563,737	7,568,738
Other Current Assets	94,407	53,648
Total Other Assets	$ 16,928,369	$ 17,374,997

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILTIES (Details) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Total Other Current Liabilities	$ 12,572,672	$ 20,278,381
Accounts Payable and Accrued Liabilities [Member]
Accounts Payable	53,330,661	58,614,619
Accrued Liabilities	9,998,881	10,532,715
Other Accrued Liabilities	12,937,196	10,383,596
Total Other Current Liabilities	$ 76,266,738	$ 79,530,930

OTHER CURRENT LIABILITIES AND_3

OTHER CURRENT LIABILITIES AND OTHER NON-CURRENT LIABILITIES (Details) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Total Other Current Liabilities	$ 12,572,672	$ 20,278,381
Total Other Current Liabilities	4,073,875	4,215,533
Other Current Liabilities and Other Non-Current Liabilities [Member]
Accrued Interest Payable	1,239,976	9,051,650
Contingent Consideration	9,254,634	8,951,801
Derivatives	240,697	546,076
Total Other Current Liabilities	1,837,365	1,728,854
Total Other Current Liabilities	$ 12,572,672	$ 20,278,381

OTHER CURRENT LIABILITIES AND_4

OTHER CURRENT LIABILITIES AND OTHER NON-CURRENT LIABILITIES (Details 1) - Derivative Liabilties [Member]	Sep. 26, 2020USD ($)
Balance As of Beginning of Year	$ 546,076
Initial Recognition of Derivative Liabilties	0
Change in Fair Value of Derivative Liabilities	(305,379)
Balance As of End of Year	$ 240,697

LEASES (Details)

LEASES (Details) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
Finance Lease Cost
Amortization of Finance Lease Right-of-Use Assets	$ 314,143	$ 2,070,767
Interest on Lease Liabilities	1,523,821	1,432,930
Operating Lease Libilities	7,658,920	6,986,299
Total lease Expenses	9,496,884	10,489,996
(Gain) and Losson Sale and Leaseback Transactions, Net	0	(704,207)
Cash Paid for Amount Includedin the Measurementof Lease Liabilities
Financing Cash Flow from Financing Leases	39,879	0
Operating Cash Flow from Operating Leases	9,158,398	7,172,043
Non Cash Additional to Right-of-Use Assets and Lease Liabilities
Recognition of Right-of-Use Assets for Finance Leases	350,249	42,676,528
Recognition of Right-of-Use Assets for Operating Leases	$ 0	$ 141,557,231
Weighted Average Remaining Lease Term (Years) - Finance Lease	38 years	48 years
Weighted Average Remaining Lease Term (Years) - Operating Lease	8 years	9 years
Weighted Average Discount Rate - Finance Lease	16.22%	10.66%
Weighted Average Discount Rate - Operating Lease	13.50%	11.35%

LEASES (Details 1)

LEASES (Details 1)	Sep. 26, 2020USD ($)
Operating Leases
June 26, 2021	$ 23,512,450
June 25, 2022	31,430,045
June 24, 2023	31,536,071
June 29, 2024	41,208,860
June 28, 2025	38,674,115
Sepetember 26, 2026 and Thereafter	126,851,773
Total lease payment	293,213,314
Less: Interest	(169,709,464)
Present Value of Lease Liabilities	123,503,850
Finance Leases
June 26, 2021	3,725,785
June 25, 2022	5,860,696
June 24, 2023	6,035,912
June 29, 2024	11,494,331
June 28, 2025	7,347,736
September 26, 2026 and Thereafter	1,080,067,137
Total lease payment	1,114,531,597
Less: Interest	(1,083,412,254)
Present Value of Lease Liabilities	$ 31,119,343

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	3 Months Ended
	Sep. 26, 2020	Jul. 02, 2020
accrued interest		8.60%
REIT [Member]
Gain on lease modification	$ 16,274,615
Warrants issued		3,500,000
Exercisable price		$ 0.34

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	Sep. 26, 2020	Jun. 30, 2020	Jun. 27, 2020
Finance liabilities incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum	$ 1,418,156		$ 1,644,044
Non-revolving, senior secured term notes dated between October 1, 2018 and September 16, 2020, issued to accredited investors, which mature on January 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum	180,042,328	$ 168,998,605
Total notes Payables	162,975,025		152,809,937
Convertible Notes Payable [Member]
Finance liabilities incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum	83,576,661		83,576,661
Non-revolving, senior secured term notes dated between October 1, 2018 and September 16, 2020, issued to accredited investors, which mature on January 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum	89,464,671		77,675,000
Convertible debentures dated September 16, 2020, issued to accredited investors and qualified institutional buyers, which mature on September 16, 2022, and bear interest at a rate of 7.5%	1,000,000		0
Promissory notes dated between January 15, 2019 through March 29, 2019, issued for deferred payments on acquisitions, which mature on varying dates from August 3, 2019 to June 30, 2020 and bear interest at rates ranging from 8.0% to 9.0% per annum	16,298,250		16,173,250
Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471	2,057,058		2,339,564
Other.	15,419		15,418
Total notes Payables	192,412,059		179,779,893
Less. Unamortization Debt Issuance Cost an Loan Origination Fess	(12,369,731)		(10,781,288)
Net Amount	180,042,328		168,998,605
Less Current Portion of Notes Payable	(17,067,303)		(16,188,668)
Notes Payables, net of Current Portion	$ 162,975,025		$ 152,809,937

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1)	3 Months Ended
	Sep. 26, 2020USD ($)
INTANGIBLE ASSETS
Balance at beginning of period Notes payables	$ 168,998,605
Cash additions	4,125,000
Non-cash Addition-Debt modification	877,439
Debt discount Recognized on modifacation	(879,267)
Paid in kind interest Capitalized	7,912,232
Cash payments	(284,334)
Equity Component of debt	(2,883,786)
Cash paid for debt issuance costs	1,828
Accreation of debt discount	2,174,611
Balance at ending of period Notes payables	180,042,328
Less Current portion of notes payables	(17,067,303)
Notes payable, Net of Current portion	$ 162,975,025

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Sep. 16, 2020	Sep. 26, 2020	Jul. 02, 2020
Fair value of the warrants in equity		$ 172,153
Warrats issued	30,000,000
Principal term Loan	$ 3,000,000		$ 77,675,000
Warrants adjusted price	$ 0.17
Warrants exercise price	$ 0.20	$ 0.60
Warrants exercisable, issued		20,227,863
Warrants exercisable, per share		$ 0.34
Existing warrants, cancelled		20,227,863
Maturity Date		Dec. 31, 2022
Additional debt discount	$ 1,579,152	$ 906,436
Amendment fee		$ 834,000
Convertible Debt [Member]
Warrants exercise price	$ 0.21
Warrants exercisable, issued	3,293,413
Proceeds convertible debenture	$ 10,000,000
Interest rate	7.50%
Additional tranches amount	$ 1,000,000
Maximum tranche amount	$ 10,000,000
Interest paid	7.50%
Conversion of debt Amount	$ 1,000,000
Conversion price	$ 0.17
Hankey Capital [Member]
Principal term Loan			$ 77,675,000
Rate of Interest			15.50%
Description		Shall accrue monthly to the outstanding principal as payment-in-kind effective March 1, 2020 through July 2, 2021. Thereafter until maturity on January 31, 2022, one-half of the interest (7.75% per annum) shall be payable monthly in cash and one-half of the interest (7.75% per annum) shall be paid-in-kind.

SENIOR SECURED CONVERTIBLE CR_3

SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details ) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Total Drawn On Senior Secured Convertible Credit Facility	$ 203,185,352	$ 187,431,400
Less Unamortize Debt Discount	(33,810,741)	(21,062,937)
Senior Secured Convertible Credit Facility Net	169,374,611	166,368,463
Secured Convertible Note 9 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	2,040,906
Secured Convertible Note 8 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	8,560,735	8,199,863
Secured Convertible Note 7 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	5,484,058
Secured Convertible Note 6 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	2,835,875	2,734,282
Secured Convertible Note 5 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	20,278,293	19,423,593
Secured Convertible Note 4 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	13,050,118	12,500,000
Secured Convertible Note 3 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	10,741,556	10,288,815
Secured Convertible Note 2 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	27,740,154	26,570,948
Secured Convertible Note 1 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	89,839,938	86,053,316
Secured Convertible Note [Member]
Total Drawn On Senior Secured Convertible Credit Facility	$ 22,613,719	$ 21,660,583

SENIOR SECURED CONVERTIBLE CR_4

SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details 1) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 26, 2020	Sep. 28, 2019
Balance at beginning of period Notes payables		$ 168,998,605
Cash additions		4,125,000
Paid-In-Kind Interest Capitalized		7,912,232
Cash Paid for Debt Issuance Costs		1,828
Amortization of Debt Discounts	$ 3,202,894		$ 3,067,535
Balance at ending of period Notes payables	180,042,328	180,042,328
2nd Restatement Fee Notes [Member]
Balance at beginning of period Notes payables		0
Cash additions		0
Fees Capitalized to Debt Related to Debt Modifications		2,000,000
Paid-In-Kind Interest Capitalized		40,906
Net Effect on Equity Component of New and Amended Debt		0
Cash Paid for Debt Issuance Costs		0
Amortization of Debt Discounts		0
Balance at ending of period Notes payables	2,040,906	2,040,906
Restatement Fee Notes [Member]
Balance at beginning of period Notes payables		7,082,065
Cash additions		0
Fees Capitalized to Debt Related to Debt Modifications		0
Paid-In-Kind Interest Capitalized		360,872
Net Effect on Equity Component of New and Amended Debt		(2,444,153)
Cash Paid for Debt Issuance Costs		0
Amortization of Debt Discounts		47,843
Balance at ending of period Notes payables	5,046,627	5,046,627
Amendment Fee Notes [Member]
Balance at beginning of period Notes payables		18,964,600
Cash additions		0
Fees Capitalized to Debt Related to Debt Modifications		0
Paid-In-Kind Interest Capitalized		854,700
Net Effect on Equity Component of New and Amended Debt		(1,193,896)
Cash Paid for Debt Issuance Costs		0
Amortization of Debt Discounts		28,685
Balance at ending of period Notes payables	18,654,089	18,654,089
Tranche 4 [Member]
Balance at beginning of period Notes payables		2,455,231
Cash additions		4,825,000
Fees Capitalized to Debt Related to Debt Modifications		468,568
Paid-In-Kind Interest Capitalized		667,205
Net Effect on Equity Component of New and Amended Debt		(2,618,335)
Cash Paid for Debt Issuance Costs		175,000
Amortization of Debt Discounts		585,518
Balance at ending of period Notes payables	6,558,187	6,558,187
Tranche 3 [Member]
Balance at beginning of period Notes payables		9,680,433
Cash additions		0
Fees Capitalized to Debt Related to Debt Modifications		0
Paid-In-Kind Interest Capitalized		452,741
Net Effect on Equity Component of New and Amended Debt		(586,606)
Cash Paid for Debt Issuance Costs		0
Amortization of Debt Discounts		31,097
Balance at ending of period Notes payables	9,577,665	9,577,665
Tranche 2 [Member]
Balance at beginning of period Notes payables		25,352,687
Cash additions		0
Fees Capitalized to Debt Related to Debt Modifications		0
Paid-In-Kind Interest Capitalized		1,169,206
Net Effect on Equity Component of New and Amended Debt		(1,492,268)
Cash Paid for Debt Issuance Costs		0
Amortization of Debt Discounts		73,947
Balance at ending of period Notes payables	25,103,572	25,103,572
Tranche 1 [Member]
Balance at beginning of period Notes payables		102,833,447
Cash additions		0
Fees Capitalized to Debt Related to Debt Modifications		0
Paid-In-Kind Interest Capitalized		4,739,758
Net Effect on Equity Component of New and Amended Debt		(5,440,833)
Cash Paid for Debt Issuance Costs		0
Amortization of Debt Discounts		261,193
Balance at ending of period Notes payables	102,393,565	102,393,565
Senior Secured Convertible, Total [Member]
Balance at beginning of period Notes payables		166,368,463
Cash additions		4,825,000
Fees Capitalized to Debt Related to Debt Modifications		2,468,568
Paid-In-Kind Interest Capitalized		8,285,388
Net Effect on Equity Component of New and Amended Debt		(13,776,091)
Cash Paid for Debt Issuance Costs		175,000
Amortization of Debt Discounts		1,028,283
Balance at ending of period Notes payables	$ 169,374,611	$ 169,374,611

SENIOR SECURED CONVERTIBLE CR_5

SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details Narrative ) - USD ($)	Sep. 14, 2020	Sep. 16, 2020	Sep. 26, 2020	Sep. 26, 2020	Sep. 28, 2019
Exercise price	$ 0.20
conversion price	$ 0.20	$ 0.17
Convertible notes	$ 468,564	$ 21,672,272
Secured convertible notes	$ 5,000,000	$ 4,883,467
Description of Note	the conversion price for 5.0% of the existing Notes outstanding prior to Tranche 4 and Incremental Advance (including paid-in-kind interest accrued on such Notes), being 5.0% of an aggregate principal amount of $170,729,923, was amended to $0.20 per share.
Warrant Issued				41,875,000
Amendment fee			$ 834,000
Loss on extinguisment of debt			$ 10,129,655		$ 31,570,116
GGP [Member]
Exercise price	$ 0.20
conversion price	$ 0.20
Secured convertible notes	$ 5,000,000
Warrant Issued	25,000,000
Cancelled Shares	1,080,255
Warrants replaced	16,875,001
GGP [Member] | On July 2, 2020[Member]
conversion price				$ 0.28
Secured convertible notes				$ 5,000,000
Description of Interest				The payment-in-kind feature on the Convertible Facility was also extended, such that 100% of the cash interest due prior to June 2021 will be paid-in-kind and 50% of the cash interest due thereafter will be paid-in-kind.
Description of Amendments Penalty				the Convertible Facility with a 5% prepayment penalty until 2nd anniversary of the Fourth Amendment and 3% prepayment penalty thereafter.
Amendment fee				$ 2,000,000
Description Of Amendments				the conversion price for 52% of the tranches 1 through 3 and the first amendment fee notes outstanding under the Convertible Facility were amended to $0.34 per share
Loss on extinguisment of debt				$ 10,129,655

SHAREHOLDERS EQUITY (Details)

SHAREHOLDERS EQUITY (Details)	3 Months Ended
	Sep. 26, 2020shares
Subordinate Voting Shares [Member]
Shares issued and outstanding, Beginning of the period	403,907,218
Shares Issued to Settle Accounts Payable and Liabilities	3,608,690
Redemption of MedMen Corp Redemable Shares	29,947,959
Shares Issued for Vested Restricted Stock Units	614,207
Stock Grant for Compensation	1,318,865
Shares issued and outstanding, End of the period	439,396,939
Super Voting Shares [Member]
Shares issued and outstanding, Beginning of the period	815,295
Shares Issued to Settle Accounts Payable and Liabilities	0
Redemption of MedMen Corp Redemable Shares	0
Shares Issued for Vested Restricted Stock Units	0
Stock Grant for Compensation	0
Shares issued and outstanding, End of the period	815,295
MM Enterprises USA Common Units [Member]
Shares issued and outstanding, Beginning of the period	725,016
Shares Issued to Settle Accounts Payable and Liabilities	0
Redemption of MedMen Corp Redemable Shares	0
Shares Issued for Vested Restricted Stock Units	0
Stock Grant for Compensation	0
Shares issued and outstanding, End of the period	725,016
MM CAN USA Class B Reedemable Units [Member]
Shares issued and outstanding, Beginning of the period	236,123,851
Shares Issued to Settle Accounts Payable and Liabilities	0
Redemption of MedMen Corp Redemable Shares	(29,947,959)
Shares Issued for Vested Restricted Stock Units	0
Stock Grant for Compensation	0
Shares issued and outstanding, End of the period	206,175,892

SHAREHOLDERS EQUITY (Details 1)

SHAREHOLDERS EQUITY (Details 1) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Jun. 27, 2020
Current Assets	$ 87,989,314		$ 84,043,732
Current Liabilities	198,094,513		189,214,893
Total Liabilities	726,512,870		751,152,054
Revenues	35,625,968	$ 39,669,996
VIEs, Total [Member]
Current Assets	2,557,111		8,683,444
Non-Current Assets	22,090,040		25,159,815
Total Assets	24,647,151		33,843,259
Current Liabilities	17,509,707		24,058,824
Non-Current Liabilities	12,899,509		15,004,985
Total Liabilities	30,409,216		39,063,809
Non-Controlling Interest	(5,762,065)		(5,220,550)
Revenues	5,684,165		24,926,268
Net (Loss) Income Attributable to Non-Controlling Interest	(546,180)		(6,766,170)
Venice Caregivers Foundation, Inc. [Member]
Current Assets	912,450		1,233,188
Non-Current Assets	13,890,323		16,867,824
Total Assets	14,802,773		18,101,012
Current Liabilities	12,471,726		12,831,161
Non-Current Liabilities	9,142,143		11,196,585
Total Liabilities	21,613,869		24,027,746
Non-Controlling Interest	(6,811,096)		(5,926,734)
Revenues	2,245,915		10,949,458
Net (Loss) Income Attributable to Non-Controlling Interest	(885,911)		(6,132,528)
Natures Cure, Inc. [Member]
Current Assets	5,913,332		6,639,231
Non-Current Assets	5,011,523		5,032,428
Total Assets	10,924,855		11,671,659
Current Liabilities	1,895,769		3,745,710
Non-Current Liabilities	1,146,331		1,146,322
Total Liabilities	3,042,100		4,892,032
Non-Controlling Interest	7,882,755		6,779,627
Revenues	3,438,820		13,976,810
Net (Loss) Income Attributable to Non-Controlling Interest	(1,103,128)		(3,143,437)
LAX Fund 2 Group, L.L.C [Member]
Current Assets	(4,268,671)		811,025
Non-Current Assets	3,188,194		3,259,563
Total Assets	(1,080,477)		4,070,588
Current Liabilities	3,142,212		7,481,953
Non-Current Liabilities	2,611,035		2,662,078
Total Liabilities	5,753,247		10,144,031
Non-Controlling Interest	(6,833,724)		(6,073,443)
Revenues	(570)		0
Net (Loss) Income Attributable to Non-Controlling Interest	$ (763,397)		$ (3,777,079)

SHAREHOLDERS EQUITY (Details 2)

SHAREHOLDERS EQUITY (Details 2) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 26, 2020	Sep. 28, 2019	Sep. 28, 2019
Net Income (Loss)	$ (32,847,403)	$ (32,847,403)	$ (62,798,699)	$ (62,798,699)
Venice Caregivers Foundation, Inc. [Member]
Shares issued and Redeemable, Beginning of the period		(5,925,185)
Net Income (Loss)		(885,911)
Equity Component on Debt and Debt Modification		$ 0
Redemption of MedMen Crop Redeemable Shares		0
Shares issued and Redemption, End of the period	(6,811,096)	$ (6,811,096)
Natures Cure, Inc. [Member]
Shares issued and Redeemable, Beginning of the period		6,779,627
Net Income (Loss)		1,103,128
Equity Component on Debt and Debt Modification		$ 0
Redemption of MedMen Crop Redeemable Shares		0
Shares issued and Redemption, End of the period	7,882,755	$ 7,882,755
LAX Fund 2 Group, L.L.C [Member]
Shares issued and Redeemable, Beginning of the period		(6,070,327)
Net Income (Loss)		(763,397)
Equity Component on Debt and Debt Modification		$ 0
Redemption of MedMen Crop Redeemable Shares		0
Shares issued and Redemption, End of the period	(6,833,724)	$ (6,833,724)
Other Non-Controlling Interests, Total [Member]
Shares issued and Redeemable, Beginning of the period		(336,777,697)
Net Income (Loss)		(10,927,541)
Equity Component on Debt and Debt Modification		$ 2,485,588
Redemption of MedMen Crop Redeemable Shares		(14,370,838)
Shares issued and Redemption, End of the period	(359,590,488)	$ (359,590,488)
Other Non Controlling Interests [Member]
Shares issued and Redeemable, Beginning of the period		(331,561,812)
Net Income (Loss)		(10,381,361)
Equity Component on Debt and Debt Modification		$ 2,485,588
Redemption of MedMen Crop Redeemable Shares		(14,370,838)
Shares issued and Redemption, End of the period	$ (353,828,423)	$ (353,828,423)

SHAREHOLDERS EQUITY (Details Na

SHAREHOLDERS EQUITY (Details Narrative)	Sep. 26, 2020	Jun. 27, 2020
Non-controlling interest, shares issued	1.40%
MM CAN USA [Member]
Non-controlling interest, shares issued	31.94%	36.89%
MM Enterprises USA Common Units [Member]
Non-controlling interest, shares issued	0.11%	0.11%

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 26, 2020	Sep. 28, 2019	Sep. 28, 2019
INTANGIBLE ASSETS
Stock Options		1,008,538	1,687,273
LTIP Units			833,531
Stock Grant for Service		181,589	364,948
Restricted Stock Grants	614,207	157,477	1,680,625	178,190
Total Share Base Compensation		$ 1,347,604	$ 4,566,377

SHARE-BASED COMPENSATION (Det_2

SHARE-BASED COMPENSATION (Details 1)	Sep. 26, 2020$ / sharesshares
INTANGIBLE ASSETS
Number of Stock Options, Beginning Balance	8,618,204
Number of Stock Options, Granted
Number of Stock Options, Forfeited	(717,794)
Number of Stock Options, Ending Balance	7,900,410
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.78
Weighted Average Exercise Price, Forfeited | $ / shares	(3.26)
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 2.74
Number of Stock Option Exerciable, Beginning Balance	4,248,393
Number of Stock Option Exerciable, Granted	896,857
Number of Stock Option Exerciable, Forfeited
Number of Stock Option Exerciable, Ending Balance	5,145,250
Weighted Average Exerciable Price, Beginning Balance | $ / shares	$ 2.78
Weighted Average Exerciable Price, Granted | $ / shares	3.48
Weighted Average Exerciable Price, Ending Balance | $ / shares	$ 3.24

SHARE-BASED COMPENSATION (Det_3

SHARE-BASED COMPENSATION (Details 2) - $ / shares	Sep. 26, 2020	Jun. 27, 2020
INTANGIBLE ASSETS
LTIP Issued And Outstanding	19,323,878	19,323,878
LIC Redeemable Units	725,016	725,016
Weighted Average grant date fair Value	$ 0.52	$ 0.52

SHARE-BASED COMPENSATION (Det_4

SHARE-BASED COMPENSATION (Details 3) - Share Based Compensation [Member]	3 Months Ended
	Sep. 26, 2020$ / sharesshares
Issued And Outstanding Beginning Balance	1,283,567
Issued And Outstanding, granted
Issued And Outstanding, Ending Balance	1,283,567
Weighted Average Fair Value, Begning Balance | $ / shares	$ 0.38
Weighted Average Fair Value, Ending Balance | $ / shares	$ 0.38

SHARE-BASED COMPENSATION (Det_5

SHARE-BASED COMPENSATION (Details 4)	3 Months Ended
	Sep. 26, 2020$ / sharesshares
INTANGIBLE ASSETS
Issued And Outstanding, Beginning Balance	7,159,164
Issued And Outstanding, Granted	614,207
Issued And Outstanding, Redemption of Vested Stock	(614,207)
Issued And Outstanding, Vesting of Restricted Stock
Issued And Outstanding, Ending Balance	7,159,164
Vested, Beginning Balance	192,459
Vested, Granted
Vested, Redemption of Vested Stock	(614,207)
Vested, Vesting of Restricted Stock	628,873
Vested, Ending Balance	207,125
Weighted Average fair Value Beginning Balance | $ / shares	$ 0.68
Weighted Average fair Value, Granted | $ / shares	0.29
Weighted Average fair Value, Redemption of Vested Stock | $ / shares	0.29
WeightedAverage Fair Value, Vesting of Restricted Stock | $ / shares	0.35
WeightedAverage Fair Value, Ending Balance | $ / shares	$ 0.68

SHARE-BASED COMPENSATION (Det_6

SHARE-BASED COMPENSATION (Details 5)	3 Months Ended
	Sep. 26, 2020$ / sharesshares
Issued	41,875,000
Warrant [Member]
Beginning Balance	155,454,646
Issued	181,213,301
Cancelled	(41,535,957)
Ending Balance	295,131,990
Weighted Average Exercise Price, Beginning balance | $ / shares	$ 0.59
Weighted Average Exercise Price, issued | $ / shares	0.17
Weighted Average Exercise Price, Cancelled | $ / shares	(0.50)
Weighted Average Exercise Price, Ending | $ / shares	$ 0.34
Warrant [Member] | MedMax Corp Redeemable Shares [Member]
Beginning Balance	40,455,731
Issued	70,455,726
Cancelled	(40,455,731)
Ending Balance	70,455,726
Warrant [Member] | Subordinate Voting Shares [Member]
Beginning Balance	114,998,915
Issued	110,757,575
Cancelled	(1,080,226)
Ending Balance	224,676,264

SHARE-BASED COMPENSATION (Det_7

SHARE-BASED COMPENSATION (Details 6)	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 16, 2020	Sep. 26, 2020	Jun. 27, 2020
INTANGIBLE ASSETS
Weighted Average Risk Free Annual Interest Rate	0.08%	0.12%	2.82%
Weighted Average Expected Annual Dividend Yield	0.00%	0.00%	0.00%
Weighted Average Expected Stock Price Volatility	52.84%	91.38%	82.93%
Weighted Average Expected Life OF Warrants	7 months 6 days	1 year	1 year

SHARE-BASED COMPENSATION (Det_8

SHARE-BASED COMPENSATION (Details 7)	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 16, 2020	Sep. 26, 2020	Jun. 27, 2020
INTANGIBLE ASSETS
Weighted Average Risk Free Annual Interest Rate	0.08%	0.12%	2.82%
Weighted Average Expected Annual Dividend Yield	0.00%	0.00%	0.00%
Weighted Average Expected Stock Price Volatility	52.84%	91.38%	82.93%
Weighted Average Expected Life OF Warrants	7 months 6 days	1 year	1 year

SHARE-BASED COMPENSATION (Det_9

SHARE-BASED COMPENSATION (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended				6 Months Ended
	Aug. 30, 2020	Sep. 26, 2020	Sep. 26, 2020	Sep. 28, 2019	Sep. 28, 2019	Jun. 27, 2020
Exercise price Maturity date			10 years
Options Outstanding			$ 58,986
Restricted Voting Shares		157,477	614,207	1,680,625	178,190
Warrant issued			41,875,000
Exercise price			$ 0.20
Cancelable Warrants			80,838,323
Warrants outstanding contractual life			53.8 months			46.2 months
DSU [Member]
Voting Shares Service Amount	$ 250,000
compensation expense			$ 157,477		$ 484,932
Shares issued			1,897,774
Minimum [Member] | Warrants [Member]
Warrant issued			30,000,000
Exercise price			$ 0.20
Minimum [Member] | Subordinate Voting Shares [Member]
Warrant issued			3,293,413
Exercise price			$ 0.21
Maximum [Member] | Warrants [Member]
Warrant issued			40,455,726
Exercise price			$ 0.34
Deferred stock units issued and outstanding			1,283,567			1,283,567
Maximum [Member] | Subordinate Voting Shares [Member]
Warrant issued			3,500,000
Exercise price			$ 0.34

LOSS PER SHARE (Details)

LOSS PER SHARE (Details) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
LOSS PER SHARE
Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc.	$ (19,237,687)	$ (21,142,349)
Less: Deemed Dividend - Down Round Feature of Warrants	(4,883,467)	0
Net Loss from Continuing Operations Available to Shareholders of MedMen Enterprises, Inc.	(24,121,154)	(21,142,349)
Net Loss from Discontinued Operations	$ (2,682,175)	$ (3,080,420)
Weighted-Average Number of Shares Outstanding	423,187,218	191,711,038
Earning (Loss) Per Share Basic and Diluted:
From Continuing Operations Attributable to Shareholders of MedMex Enterprises, Inc.	$ (0.06)	$ (0.11)
From Discontinued Operations	$ (0.01)	$ (0.02)

GENERAL AND ADMINISTRATIVE EX_3

GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 26, 2020	Sep. 28, 2019	Sep. 28, 2019
Total General and Administrative Expenses		$ 31,683,604	$ 54,094,949
General And Administrative Expenses [Member]
Salaries and Benefits	$ 10,040,704			$ 20,901,335
Professional Fees	3,599,335			5,285,269
Rent	8,607,733			7,134,515
Licenses, Fees and Taxes	3,250,878			2,321,899
Other General and Administrative Expenses	6,184,954			18,451,931
Total General and Administrative Expenses	$ 31,683,604			$ 54,094,949

PROVISION FOR INCOME TAXES AN_3

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES
Loss from Continuing Operations Before Provision for Income Taxes	$ (19,826,666)	$ (77,379,010)
Income Tax (Expense) Benefit	$ (10,338,562)	$ 17,660,731
Effective Tax Rate	(52.04%)	(22.82%)

PROVISION FOR INCOME TAXES AN_4

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details Narrative)	3 Months Ended
	Sep. 26, 2020USD ($)
PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES
Net operating losses	$ 76,700,000
Unrealized net operating loss	$ 2,500,000
Expiring term	2038

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)	Jul. 31, 2018USD ($)
COMMITMENTS AND CONTINGENCIES
Legal claim damages	$ 2,200,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Amounts due from related parties	$ 3,109,718	$ 3,109,717
MedMen Opportunity Fund GP LLC [Member]
Amounts due from related parties	1,289,514	1,289,513
MMOF GP II, LLC [Member]
Amounts due from related parties	$ 1,820,204	$ 1,820,204

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Amounts due to related parties	$ 4,553,715	$ 4,556,814
Fund I.P II [Member]
Amounts due to related parties	(1,093,896)	(1,093,896)
Fund I.P [Member]
Amounts due to related parties	(1,986,697)	(1,986,697)
Other [Member]
Amounts due to related parties	(1,473,122)	(1,476,221)
Related Party Transactions [Member]
Amounts due to related parties	$ (4,553,715)	$ (4,556,814)

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Sep. 26, 2020	Aug. 31, 2020	Dec. 11, 2019
Restructuring support fees paid	$ 699,322
Mr. Rose [Member]
Deferred stock granted		102,519	815,295

DISCONTINUED OPERATIONS (Detail

DISCONTINUED OPERATIONS (Details) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 26, 2020	Sep. 28, 2019	Sep. 28, 2019	Sep. 28, 2019
Revenue	$ 35,625,968			$ 39,669,996
Cost of goods sold	62,447		$ 942,542
Gross Profit	16,824,058			19,392,176
Expenses:
General and Administrative	31,683,604			54,094,949
Sales and Marketing	193,385			5,782,780
Depreciation and Amortization	3,352,854		$ 3,359,970
Total Expenses	24,897,379			70,948,002
Income (Loss) from Operations	$ (8,073,321)			$ (51,555,826)
Other Expense (Income):
Loss on Discontinued Operations Before Provision for Income Taxes		$ (19,826,666)			$ (77,379,010)
Loss on Discontinued Operations		(2,682,175)			(3,080,420)
Arizona [Member]
Revenue		1,599,990			4,304,749
Cost of goods sold		1,268,752			3,880,606
Gross Profit		331,238			424,143
Expenses:
General and Administrative		976,611			1,823,752
Sales and Marketing		6,501			948
Depreciation and Amortization		49,142			499,328
Total Expenses		1,032,254			2,324,028
Income (Loss) from Operations		(701,016)			(1,899,885)
Other Expense (Income):
Other expense		37,056			5,385
Total Other Expense		37,056			5,385
Loss on Discontinued Operations Before Provision for Income Taxes		(738,072)			(1,905,270)
Provision for Income Tax (Expense) Benefit		(1,944,103)			(1,175,150)
Loss on Discontinued Operations		$ (2,682,175)			$ (3,080,420)

DISCONTINUED OPERATIONS (Deta_2

DISCONTINUED OPERATIONS (Details 1) - USD ($)	Sep. 26, 2020	Jun. 27, 2020
Carraying Amounts of the Assets Included in Discontinued Operations:
Cash and Cash Equivalents	$ 10,310,260	$ 10,093,925
Inventory	21,294,149	22,638,120
Other Current Assets	15,768,919	9,105,457
Property and Equipment, Net	156,197,545	174,547,867
Operating Lease Right-of-Use Assets	100,762,121	116,354,828
Other Assets	16,928,369	17,374,997
TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE	534,176,277	574,263,604
Carraying Amounts of the Liabilities Included in Discontinued Operations:
Income Taxes Payable	57,663,832	38,599,349
Total Other Current Liabilities	12,572,672	20,278,381
Current Portion of Operating Lease Liabilities	8,206,432	9,757,669
Operating Lease Liabilities, Net of Current Portion	115,297,418	131,045,238
Total Liabilities	726,512,870	751,152,054
Arizona [Member]
Carraying Amounts of the Assets Included in Discontinued Operations:
Cash and Cash Equivalents	319,834	522,966
Accounts Receivable	239,702	274,886
Prepaid Expenses	59,921	74,622
Inventory	3,241,697	3,323,978
Other Current Assets	65,851	64,600
Property and Equipment, Net	4,224,082	4,288,808
Operating Lease Right-of-Use Assets	5,136,228	5,257,327
Intangible Assets, Net	7,298,804	7,260,288
Other Assets	117,275	113,576
TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE	20,703,394	24,181,051
Carraying Amounts of the Liabilities Included in Discontinued Operations:
Accounts Payable and Accrued Liabilities	1,732,280	2,126,162
Income Taxes Payable	2,818,170	946,679
Total Other Current Liabilities	22,462	22,747
Current Portion of Operating Lease Liabilities	379,529	385,699
Operating Lease Liabilities, Net of Current Portion	5,199,132	5,300,936
Deferred Tax Liabilities	6,278,078	6,278,079
Total Liabilities	$ 16,429,651	$ 15,060,302

DISCONTINUED OPERATIONS (Deta_3

DISCONTINUED OPERATIONS (Details Narrative)	1 Months Ended
	Jun. 27, 2020USD ($)
DISCONTINUED OPERATIONS
Gross proceeds from operations	$ 25,500,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended			3 Months Ended
	Nov. 20, 2020	Oct. 30, 2020	Sep. 28, 2020	Sep. 26, 2020
Sales price				$ 25,000,000
Subsequent Event [Member]
Interest rate on term loan		18.00%
Interest rate paid in cash		12.00%
Accrued interest rate		6.00%
Unsecured convertible facility	$ 1,000,000	$ 1,000,000
Exercisable warrants issued	3,592,326	77,052,790	3,777,475
Exercise price of warrants	$ 0.21	$ 0.20	$ 0.21
Maturity period for warrants		5 years
Incremental term loan		$ 7,700,000
Issuance of subordinate voting share			$ 1,000,000
Conversion price	$ 0.17	$ 0.17	$ 0.17

CORRECTION OF ERROR IN PREVIO_3

CORRECTION OF ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
Revenue	$ 35,625,968	$ 39,669,996
Cost of Goods Sold	18,801,910	20,277,820
Gross Profit	16,824,058	19,392,176
Expenses:
General and Administrative	31,683,604	54,094,949
Sales and Marketing	193,385	5,782,780
Depreciation and Amortization	8,625,708	9,484,181
Realized and Unrealized Loss on Changes in Fair Value of Contingent Consideration	(302,834)	(2,284,054)
Impairment Expense	789,709	0
Gain On Disposals of Assets, Restructuring Fees and Other Expenses	(16,697,861)	(697,962)
Total Expenses	24,897,379	70,948,002
Loss from Operations	(8,073,321)	(51,555,826)
Other Expense (Income):
Interest Expense	11,142,864	8,163,617
Interest Income	(1,210)	(369,342)
Amortization of Debt Discount and Loan Origination Fees	3,202,894	3,067,535
Change in Fair Value of Derivatives	(305,379)	(5,128,420)
Realized and Unrealized Gain on Investments, Assets Held For Sale and Other Assets	(12,415,479)	(11,480,322)
Loss on Extinguishment of Debt	10,129,655	31,570,116
Total Other Expense	11,753,345	25,823,184
Loss from Continuing Operations Before Provision for Income Taxes	(19,826,666)	(77,379,010)
Net Loss from Continuing Operations	(30,165,228)	(59,718,279)
Net Loss from Discontinued Operations, Net of Taxes	(2,682,175)	(3,080,420)
Net Loss Attributable to Shareholders of MedMen Enterprises Inc.	$ (21,919,862)	$ (24,222,769)
Loss Per Share - Basic and Diluted:
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.	$ (0.06)	$ (0.11)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.	$ (0.01)	$ (0.02)
Weighted-Average Shares Outstanding - Basic and Diluted	423,187,218	191,711,038
As Corrected [Member]
Revenue		$ 39,669,996
Cost of Goods Sold		20,277,820
Gross Profit		19,392,176
Expenses:
General and Administrative		54,094,949
Sales and Marketing		5,782,780
Depreciation and Amortization		9,484,181
Realized and Unrealized Loss on Changes in Fair Value of Contingent Consideration		2,284,054
Impairment Expense		0
Gain On Disposals of Assets, Restructuring Fees and Other Expenses		(697,962)
Total Expenses		70,948,002
Loss from Operations		(51,555,826)
Other Expense (Income):
Interest Expense		8,163,617
Interest Income		(369,342)
Amortization of Debt Discount and Loan Origination Fees		3,067,535
Change in Fair Value of Derivatives		(5,128,420)
Realized and Unrealized Gain on Investments, Assets Held For Sale and Other Assets		(11,480,322)
Loss on Extinguishment of Debt		31,570,116
Total Other Expense		25,823,184
Loss from Continuing Operations Before Provision for Income Taxes		(77,379,010)
Provision for Income Tax Expense		17,660,731
Net Loss from Continuing Operations		(59,718,279)
Net Loss from Discontinued Operations, Net of Taxes		(3,080,420)
Net Loss		(62,798,699)
Net Loss Attributable to Non-Controlling Interest		(38,575,930)
Net Loss Attributable to Shareholders of MedMen Enterprises Inc.		$ (24,222,769)
Loss Per Share - Basic and Diluted:
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.		$ (0.11)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.		$ (0.02)
Weighted-Average Shares Outstanding - Basic and Diluted		191,711,038
Adjustment [Member]
Revenue		$ 0
Cost of Goods Sold		0
Gross Profit		0
Expenses:
General and Administrative		0
Sales and Marketing		0
Depreciation and Amortization		0
Realized and Unrealized Loss on Changes in Fair Value of Contingent Consideration		0
Impairment Expense		0
Gain On Disposals of Assets, Restructuring Fees and Other Expenses		0
Total Expenses		0
Loss from Operations		0
Other Expense (Income):
Interest Expense		0
Interest Income		0
Amortization of Debt Discount and Loan Origination Fees		0
Change in Fair Value of Derivatives		0
Realized and Unrealized Gain on Investments, Assets Held For Sale and Other Assets		0
Loss on Extinguishment of Debt		0
Total Other Expense		0
Loss from Continuing Operations Before Provision for Income Taxes		0
Net Loss from Continuing Operations		23,681,253
Net Loss from Discontinued Operations, Net of Taxes		774,633
Net Loss		24,455,886
Net Loss Attributable to Shareholders of MedMen Enterprises Inc.		$ (8,869,996)
Loss Per Share - Basic and Diluted:
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.		$ 0.04
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.		$ 0
Weighted-Average Shares Outstanding - Basic and Diluted
Provision for Income Tax Expense		$ 23,681,253
Net Loss Attributable to Non-Controlling Interest		15,585,890
Previously Reported [Member]
Revenue		39,669,996
Cost of Goods Sold		20,277,820
Gross Profit		19,392,176
Expenses:
General and Administrative		54,094,949
Sales and Marketing		5,782,780
Depreciation and Amortization		9,484,181
Realized and Unrealized Loss on Changes in Fair Value of Contingent Consideration		2,284,054
Impairment Expense		0
Gain On Disposals of Assets, Restructuring Fees and Other Expenses		(697,962)
Total Expenses		70,948,002
Loss from Operations		(51,555,826)
Other Expense (Income):
Interest Expense		8,163,617
Interest Income		(369,342)
Amortization of Debt Discount and Loan Origination Fees		3,067,535
Change in Fair Value of Derivatives		(5,128,420)
Realized and Unrealized Gain on Investments, Assets Held For Sale and Other Assets		(11,480,322)
Loss on Extinguishment of Debt		31,570,116
Total Other Expense		25,823,184
Loss from Continuing Operations Before Provision for Income Taxes		(77,379,010)
Net Loss from Continuing Operations		(83,399,532)
Net Loss from Discontinued Operations, Net of Taxes		(3,855,053)
Net Loss		(87,254,585)
Net Loss Attributable to Shareholders of MedMen Enterprises Inc.		$ (33,092,765)
Loss Per Share - Basic and Diluted:
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.		$ (0.15)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.		$ (0.02)
Weighted-Average Shares Outstanding - Basic and Diluted		191,711,038
Provision for Income Tax (Expense) Benefit		$ (6,020,522)
Net Loss Attributable to Non-Controlling Interest		$ 54,161,820

CORRECTION OF ERROR IN PREVIO_4

CORRECTION OF ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details 1)	3 Months Ended
	Sep. 28, 2019USD ($)
As Corrected [Member]
BALANCE AS OF JUNE 30, 2019	$ 211,270,776
Net Loss	(62,798,699)
Controlling Interest Equity Transactions	58,440,324
Non-Controlling Interest Equity Transactions	(921,778)
BALANCE AS OF SEPTEMBER 28, 2019	205,990,623
Previously Reported [Member]
BALANCE AS OF JUNE 30, 2019	211,270,776
Net Loss	(87,254,585)
Controlling Interest Equity Transactions	58,440,324
Non-Controlling Interest Equity Transactions	(921,778)
BALANCE AS OF SEPTEMBER 28, 2019	1,181,534,737
Adjustment Impacts [Member]
BALANCE AS OF JUNE 30, 2019	0
Net Loss	24,455,886
Controlling Interest Equity Transactions	0
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	24,455,886
Additional Paid-in Capital [Member] | As Corrected [Member]
BALANCE AS OF JUNE 30, 2019	613,356,006
Net Loss	0
Controlling Interest Equity Transactions	78,636,466
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	691,992,472
Additional Paid-in Capital [Member] | Previously Reported [Member]
BALANCE AS OF JUNE 30, 2019	613,356,006
Net Loss	0
Controlling Interest Equity Transactions	78,636,466
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	691,992,472
Additional Paid-in Capital [Member] | Adjustment Impacts [Member]
BALANCE AS OF JUNE 30, 2019	0
Net Loss	0
Controlling Interest Equity Transactions	0
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	0
Noncontrolling Interest [Member] | As Corrected [Member]
BALANCE AS OF JUNE 30, 2019	(31,867,405)
Net Loss	(38,575,930)
Controlling Interest Equity Transactions	(210,120)
Non-Controlling Interest Equity Transactions	(921,778)
BALANCE AS OF SEPTEMBER 28, 2019	(71,575,233)
Noncontrolling Interest [Member] | Previously Reported [Member]
BALANCE AS OF JUNE 30, 2019	(31,867,405)
Net Loss	(54,161,820)
Controlling Interest Equity Transactions	(210,120)
Non-Controlling Interest Equity Transactions	(921,778)
BALANCE AS OF SEPTEMBER 28, 2019	(87,161,123)
Noncontrolling Interest [Member] | Adjustment Impacts [Member]
BALANCE AS OF JUNE 30, 2019	0
Net Loss	15,585,890
Controlling Interest Equity Transactions	0
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	15,585,890
TOTAL EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF MEDMEN [Member] | As Corrected [Member]
BALANCE AS OF JUNE 30, 2019	243,138,181
Net Loss	(24,222,769)
Controlling Interest Equity Transactions	58,650,444
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	277,565,856
TOTAL EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF MEDMEN [Member] | Previously Reported [Member]
BALANCE AS OF JUNE 30, 2019	243,138,181
Net Loss	(33,092,765)
Controlling Interest Equity Transactions	58,650,444
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	268,695,860
TOTAL EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF MEDMEN [Member] | Adjustment Impacts [Member]
BALANCE AS OF JUNE 30, 2019	0
Net Loss	8,869,996
Controlling Interest Equity Transactions	0
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	8,869,996
Accumulated Deficit [Member] | As Corrected [Member]
BALANCE AS OF JUNE 30, 2019	(370,382,824)
Net Loss	(24,222,769)
Controlling Interest Equity Transactions	(19,986,022)
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	(414,591,615)
Accumulated Deficit [Member] | Previously Reported [Member]
BALANCE AS OF JUNE 30, 2019	(370,382,824)
Net Loss	(33,092,765)
Controlling Interest Equity Transactions	(19,986,022)
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	(423,461,611)
Accumulated Deficit [Member] | Adjustment Impacts [Member]
BALANCE AS OF JUNE 30, 2019	0
Net Loss	8,869,996
Controlling Interest Equity Transactions	0
Non-Controlling Interest Equity Transactions	0
BALANCE AS OF SEPTEMBER 28, 2019	$ 8,869,996

CORRECTION OF ERROR IN PREVIO_5

CORRECTION OF ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details 2) - USD ($)	3 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
Net Loss from Continuing Operations	$ (30,165,228)	$ (59,718,279)
Income Taxes Payable	19,064,475	(16,207,725)
NET CASH USED IN CONTINUED OPERATING ACTIVITIES	(16,958,314)	(45,047,288)
Net Cash Provided by Discontinued Operating Activities	(1,194,616)	2,980,952
NET CASH USED IN OPERATING ACTIVITIES	(18,152,930)	(42,066,336)
NET CASH USED IN INVESTING ACTIVITIES	(9,743,478)	13,149,929
NET CASH PROVIDED BY FINANCING ACTIVITIES	8,625,787	63,698,694
NET INCREASE IN CASH AND CASH EQUIVALENTS	216,335	8,482,429
Cash and Cash Equivalents, Beginning of Period	10,093,925	33,753,747
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 10,310,260	42,236,176
As Corrected [Member]
Net Loss from Continuing Operations		(59,718,279)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:		43,348,526
Income Taxes Receivable		0
Income Taxes Payable		16,207,725
Operating Assests and Liabilities		(12,469,810)
NET CASH USED IN CONTINUED OPERATING ACTIVITIES		(45,047,288)
Net Cash Provided by Discontinued Operating Activities		2,980,952
NET CASH USED IN OPERATING ACTIVITIES		(42,066,336)
NET CASH USED IN INVESTING ACTIVITIES		(13,149,929)
NET CASH PROVIDED BY FINANCING ACTIVITIES		63,698,694
NET INCREASE IN CASH AND CASH EQUIVALENTS		8,482,429
Cash and Cash Equivalents, Beginning of Period		33,753,747
CASH AND CASH EQUIVALENTS, END OF PERIOD		42,236,176
Adjustment [Member]
Net Loss from Continuing Operations		23,681,253
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:		0
Income Taxes Receivable		2,994,072
Income Taxes Payable		27,449,958
Operating Assests and Liabilities		0
NET CASH USED IN CONTINUED OPERATING ACTIVITIES		(774,633)
Net Cash Provided by Discontinued Operating Activities		774,633
NET CASH USED IN OPERATING ACTIVITIES		0
NET CASH USED IN INVESTING ACTIVITIES		0
NET CASH PROVIDED BY FINANCING ACTIVITIES		0
NET INCREASE IN CASH AND CASH EQUIVALENTS		0
Cash and Cash Equivalents, Beginning of Period		0
CASH AND CASH EQUIVALENTS, END OF PERIOD		0
Previously Reported [Member]
Net Loss from Continuing Operations		(83,399,532)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:		43,348,526
Income Taxes Receivable		(2,994,072)
Income Taxes Payable		11,242,233
Operating Assests and Liabilities		(12,469,810)
NET CASH USED IN CONTINUED OPERATING ACTIVITIES		(44,272,655)
Net Cash Provided by Discontinued Operating Activities		2,206,319
NET CASH USED IN OPERATING ACTIVITIES		(42,066,336)
NET CASH USED IN INVESTING ACTIVITIES		(13,149,929)
NET CASH PROVIDED BY FINANCING ACTIVITIES		63,698,694
NET INCREASE IN CASH AND CASH EQUIVALENTS		8,482,429
Cash and Cash Equivalents, Beginning of Period		33,753,747
CASH AND CASH EQUIVALENTS, END OF PERIOD		$ 42,236,176